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1.  Introduction 
1.1  Occurrence of Sialic Acids 
1.1.1  Structural Basis for Diversity in Sialic Acids 
Since the first discovery of sialic acids at the end of the 1930s, more than 50 naturally 
occurring derivatives have been found [1;2]. Structurally, sialic acids are a family of acidic 
nine-carbon sugars, originally described as derivatives of 5-amino-3,5-dideoxy-D-glycero-D-
galacto-non-2-ulosonic acid (neuraminic acid; Neu). The most widespread form is 5-
acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid (N-acetylneuraminic 
acid; Neu5Ac), which is believed to be the biosynthetic precursor for all other members of the 
family. Hydroxylation of the N-acetyl group leads to 5-hydroxyacetamido-3,5-dideoxy-D-
glycero-D-galacto-non-2-ulopyranosonic acid (N-glycolyneuraminic acid; Neu5Gc), which 
occurs frequently in many animal species, but has been found in humans only in the case of 
particular cancer [2;3]. The 5-amino group can be replaced by a hydroxyl group, yielding 3-
deoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid (Kdn). Further structural variation of 
sialic acids arises from substitutions of one or more of the hydroxyl groups of Neu5Ac, 
Neu5Gc or Kdn with acetyl, methyl, lactyl, phosphate or sulphate groups, or introduction of a 
double bond between C-2 and C-3 [2;4]. 
 
 
OH
COOH
R    HN
HO
2
3
4
5
789
1
HO
HO
HO
O
A
OH
COOH
HO
2
3
4
5
789
1
HO
HO
HO
O
B
HO
 
 
Figure 1-1 Structures of Sialic Acids. A: Neuraminic acid (Neu, R=H-); N-acetylneuraminic acid 
(Neu5Ac, R=CH3CO-); N-glycolyneuraminic acid (Neu5Gc, R=HOCH2CO-). B: 3-deoxy-D-glycero-D-galacto-
non-2-ulopyranosonic acid (Kdn). 
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1.1.2  Distribution of Sialic Acids in Nature 
Sialic acids have mainly been found in the animal kingdom, from the echinoderms to 
humans [1;2]. It has been reported that sialic acids are also present in some viruses, various 
bacteria, protozoa, and pathogenic fungi [1;2;4].  
    Generally, sialic acids are localized at the terminal position of a glycan chain on 
glycoproteins and glycolipids as well as oligosaccharides, and are either α2,3- or α2,6-linked 
to D-galactose (Gal), α2,3- or α2,6-linked to N-acetyl-D-galactosamine (GalNAc), α2,6-
linked to N-acetyl-D-glucosamine (GlcNAc), or α2,8-linked to other sialic acids [2].  
 
1.1.3 O-Acetylated Sialic Acids and the Spontaneous Migration of O-Acetyl 
Groups  
O-Acetylation is one of the most common modifications that occur on sialic acids. It can 
occur either at position 4 of the pyranose ring [5;6], or at position 7, 8 and 9 of the glycerol 
side chain of sialic acids [2;4;7;8]. One interesting chemical property of O-acetylated sialic 
acids is that the O-acetyl group at position 7- or 8- can spontaneously migrate to an un-
substituted hydroxyl at position 9 [9;10]. The migration rate of 8-O-acetyl group is too fast to 
isolate the compound in a stable state. In contrast, the migration half-life of free Neu5,7Ac2 is 
4-8 h at physiological conditions (37 °C, pH 7.0) [9]. However, the migration rate is 
considerably slower at 37 °C, pH 6.5. Although it has not been accurately determined, the 
migration of O-acetyl groups on glycosidically linked sialic acids is assumed to be similar. 
    The migration of O-acetyl groups might be significant for the biosynthesis and biological 
properties of O-acetylated sialic acids. In vivo, it is possible that O-acetylated sialic acids on 
specific molecules are first expressed at the cell surface as Neu5,7Ac2, whose 7-O-acetyl 
groups could subsequently migrate to the 9-position over time. As a result, the recognition or 
biological properties of the underlying molecules are altered due to a change in 
structure [4;7]. 
 
1.1.4  Biological Roles of O-Acetylated Sialic Acids 
The distribution of O-acetylated sialic acids was first thought to be a species-specific 
determinant, since Neu5,9Ac2 was found in bovine submandibular gland mucin, and 
Neu5,4Ac2 in equine submandibular gland mucin [2;4;7]. However, with the improvement in 
analytical techniques, O-acetylated sialic acids have been found nearly in all higher animals 
and certain bacteria, suggesting an important biological role of these molecules. We are just at 
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the beginning of understanding this aspect, however, more and more evidences suggest that 
O-acetylated sialic acids be involved into many physiological and pathological processes 
(Table 1-1). 
 
Table 1-1 Physiological Functions of O-Acetylated Sialic Acids. 
 
Effect References 
Modification of the physicochemical properties of glycoconjugates. [8;11] 
Hindrance of the action of sialidase, trans-sialidase, sialate-pyruvate-lyase 
etc. 
[2;8] 
Targets for a variety of microbial and viral proteins such as influenza C 
virus, mouse hepatitis virus, coronavirus, encephalomyelitis virus. 
[12-14] 
Masking the recognition sites, e.g., for influenza A and B viruses,  
Plasmodium falciparum, sialoadhesin, CD22 and MAG. 
[15;16] 
As the specific ligands playing important roles in cell and molecule 
recognition phenomena, for example, as the epitopes for recognition by 
antibodies and lectins. 
[2;8;11] 
Tumor associated antigens, e.g., human melanoma (9-O-Ac-GD3), 
basalioma (9-O-Ac-GD3). 
[2;7;17;18] 
 
 
1.2  Metabolism of Sialic Acids  
The main pathway of sialic acids metabolism has been clarified. Figure 1-2 summarizes the 
basic steps in the eukaryotic cells, and the subcellular localizations of the main enzymes 
involved [2]. Free Neu5Ac is synthesized in the cytosol, which is activated to CMP-Neu5Ac 
in the nucleus. En route, CMP-Neu5Ac can be hydroxylated to yield CMP-Neu5Gc by the 
CMP-Neu5Ac hydroxylase. In the Golgi apparatus, sialic acids are transferred from CMP-
sialic acids to glycoconjugates by sialyltransferases. The sialic acids on glycoconjugates can 
be further modified.  
    The degradation of un-substituted sialic acids begins with the hydrolysis of sialic acids by 
sialidase that is located in the lysosome. In some cases, modification present on sialic acids 
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hinders the action of sialidases, thus, other enzymes are required to remove these 
modifications to facilitate the action of sialidases. Free sialic acids are transported from the 
lysosomal compartment to the cytosol, and are re-utilized or degraded by a cytosolic sialate-
pyruvate-lyase. 
 
 
Cytosol
Glc
GlcNH2-6-P
GlcNAc-6-P
GlcNAc-1-P
GlcNAc
ManNAc-6-P
ManNAc
UDP-GlcAc
Neu5Ac-9-P
Neu5Ac
Neu5Ac
Neu5Ac
Neu5Ac
CMP-Neu5Ac
CMP-Neu5Ac
Neu5Ac
CMP-Neu5Ac
CMP
CMP
LysosomeManNAc
      +
Pyruvate
1
2
3
4
5
CMP-Neu5Gc
6
7
7
Nucleus
Golgi
 
Figure 1-2 General Metabolic Pathway of Sialic Acids. The general pathway for the biosynthesis, 
activation, transfer, and eventual recycling of sialic acids is indicated. 1, sialate-pyruvate-lyase; 2, sialidase; 
3, CMP sialic acid synthase; 4, CMP-sialic acid transporter; 5, sialyltransferase; 6, CMP-Neu5Ac hydroxylase; 
7, glycoconjugates. 
 
 
1.2.1  CMP-Sialic Acid Transporter  
Once CMP-sialic acids are formed, they are transported into the lumen of the Golgi apparatus, 
where they are utilized for the sialylation of glycoconjugates [2]. The transport of CMP-sialic 
acid is mediated by a highly specific transporter [19-22]. In mammals, studies in vitro 
strongly suggest that the CMP-sialic acid transporter is an antiporter that delivers CMP-sialic 
acids into the Golgi lumen with the simultaneous counter-transport of CMP, the reaction 
product following sialylation of proteins and lipids [19;20]. The CMP-Neu5Ac transporter has 
a very high affinity for its substrate, with a KM in the range of 1 to 10 µM [21-23]. Moreover, 
this procedure is not energy-dependent, and can be competitively inhibited by the 
corresponding nucleoside mono- and diphosphate, but not by sialic acids [19;22;24]. 
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    In the past few years, several CMP-sialic acid transporter genes have been cloned [24-28]. 
However, little is known about the regulation of CMP-sialic acid translocation, and the 
influence of CMP-sialic acid transporter on the sialylation.  
 
1.2.2  Sialyltransferase  
Sialyltransferases are a subset of the glycosyltransferase family that utilize CMP-sialic acids 
as the activated sugar donor to catalyze the transfer of sialic acid residues to terminal non-
reducing positions of oligosaccharide chains on glycoproteins and glycolipids [2;29]. These 
enzymes have been shown to be restricted to the trans cisternae of the Golgi apparatus and the 
trans Golgi network [2]. However, in some cases, these enzymes may have a more diffuse 
distribution throughout the Golgi apparatus in some cells [30;31]. 
    In general, each sialic acid linkage is generated by a single or more sialyltransferases which 
show the specificity not only for the linkage but also for the acceptor [2;29]. In mammalian 
systems, sialic acids are usually α2,3- or α2,6-linked to Gal and GalNAc of the glycan on 
glycoproteins. Further structural subdivision can be made according to the type of the 
underlying oligosaccharide chain involved, i.e., O-linked or N-linked [2;29;32]. In 
gangliosides, sialic acids are found to be α2,8-linked to other sialic acids [2]. Till now, a 
family of distinct sialyltransferase gene products have been identified that can transfer sialic 
acid onto the oligosaccharides on glycoproteins or gangliosides [29].  
 
1.2.3  Metabolism of the O-Acetyl Group on Sialic Acids 
The two main enzymes involved in the metabolism and catabolism of O-acetylated sialic 
acids are acetyl-coenzyme A:sialate-O-acetyltransferase (OAT) for the O-acetylation of sialic 
acids, and sialate-O-acetylesterase (OAE) for the de-O-acetylation of O-acetylated sialic 
acids. 
 
1.2.3.1  Acetyl-Coenzyme A:Sialate-O-Acetyltransferase (OAT) 
At least two OATs are known to introduce acetyl group into sialic acids, using AcCoA as the 
donor substrate [33;34]. The acetyl-coenzyme A:sialate-4-O-acetyltransferase (EC 2.3.1.44; 
4-OAT) [2;4] is responsible for the O-acetylation of the hydroxyl group located on the 
pyranose ring of sialic acid. The enzyme is absolutely specific with regard to the insertion site 
of the acetyl group at C-4. In contrast to 4-OAT, the exact primary attachment site of the 
acetyl-coenzyme A:sialate 7(9)-O-acetyltransferases (EC 2.3.1.45; 7(9)-OAT) [2;4] is not 
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known. What is known is that these enzymes incorporate acetyl groups onto the glycerol side 
chain of sialic acid, probably at position 7, followed by migration to C-9 [9;35]. Therefore, 
this enzyme is addressed as 7(9)-OAT. However, the available data do not exclude the 
possibility that two separate O-acetyl transferases specific for 7- and 9-O-acetylation exist. 
    Investigations on OATs in different tissues [5;6;35-38] show that these enzymes are 
membrane-bound, co-localized with sialyltransferases, and utilize glycosidically linked sialic 
acids as the acceptor substrate. O-Acetylation of sialic acids predominantly takes place in the 
Golgi apparatus, which requires the cooperation of a putative acetyl-CoA transporter [36]. 
Similar results were also obtained for the O-acetylation of gangliosides in Golgi-enriched 
vesicles from human melanoma cells [38].  
    However, a cytosolic 7(9)-OAT activity has been identified in bovine and equine 
submandibular glands, which could transfer acetyl groups from AcCoA to either exogenous 
or endogenous free sialic acids [39]. Till now, the existence of a true cytosolic enzyme is still 
an open question, which might result from the partial solubilization of membrane-bound 
enzyme during the homogenization procedure. However, the possibility that sialate O-
acetylation happens prior to the sialylation of glycoconjugates cannot be excluded, since 
CMP-Neu5,9Ac2 isolated from bovine submandibular glands has been found to be utilized by 
the STs in the microsomes of the same tissues [39;40]. 
    Unfortunately, even though OATs were discovered some 30 years ago [33;34], they have 
proven intractable to be purified to homogeneity. Attempts to clone one of the sialate-O-
acetyltransferase gene(s) have also been unsuccessful, and attempts at expression cloning 
resulted in the identification of proteins capable of inducing O-acetylation of sialic acids but 
not the enzyme itself [41;42]. Several groups have cloned genes encoding the putative AcCoA 
transporter [43-45], which can transfer AcCoA into the Golgi apparatus, and is involved in the 
O-acetylation of gangliosides. However, these putative AcCoA transporters show high 
degrees of homology to the putative transmembrane protein (EMBL) from Saccharomyces 
cerevisiae and Caenorhabditis elegans, in which neither gangliosides nor sialic acids are 
expressed. Ogura et al. (1996) [46] cloned a putative sialate-O-acetyltransferase specific for 
GD3 but the deduced amino sequence showed significant homology with a mouse milk fat 
globule membrane protein. These data suggest that caution should be paid to the results 
obtained from expression cloning, because unrelated proteins can induce O-acetylation of 
sialic acids. 
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1.2.3.2  Sialate-O-Acetylesterase (OAE) 
O-Acetyl groups of sialic acids can be removed by esterases specific for O-acetylated sialic 
acids. Several of these enzymes have been found in viruses [47-51], bacteria [52] and 
vertebrates [53-55], showing different substrate specificities. The esterase specific for 4-O-
acetyl groups of sialic acids is called sialate-4-O-acetylesterase (4-OAE) [48;51], and the one 
for 9-O-acetyl groups is sialate-9-O-acetylesterase (EC 3.1.1.53, 9-OAE) [53;54;56]. 
    Influenza C virus specifically recognizes Neu5,9Ac2 [57], and the receptor-destroying 
enzyme of this virus has been characterized as sialate-9-O-acetylesterase [48]. This unique 
property of influenza C virus makes it a very useful and specific tool to investigate either free 
or glycosidically linked 9-O-acetylated sialic acids [58-60]. 
    In mammals [53;55], most OAEs appear to be highly specific for the cleavage of 9-O-
acetyl groups from sialic acids. However, esters from the 7- or 8-position can be indirectly 
removed [53], after they have migrated to the 9-position [9;35]. Moreover, an esterase 
specific for sialate-4-O-acetyl groups has been found in equine tissues [54]. 
    The data currently available demonstrate the existence of two 9-OAEs belonging to the 
diisopropylfluorophosphate (DFP)-sensitive esterase family [61;62]. One  is localized in the 
cytosol (Cse) and the other in the lysosomal/endososomal compartment (Lse). The latter is a 
water-soluble N-linked glycoprotein that transits the Golgi apparatus during its biosynthesis, 
and undergoes a late proteolytic cleavage possibly resulting in an increase in the enzyme 
activity [63]. Interestingly, a portion of the newly synthesized Lse is secreted as an uncleaved 
form [63], however, the biological significance of this enzyme form is unclear. 
    In contrast to Lse, Cse is a non-glycosylated protein [53;56;61]. Nevertheless, it has been 
reported that Lse and Cse of mouse liver could be encoded by one gene via differential usage 
of a signal peptide-encoding exon at the N-terminus [64]. This suggests that at least part of the 
Cse activity results from the alternate cytosolic form derived from the lse gene.  
    It has been postulated that Lse and Cse may play different roles in the catabolism of O-
acetylated sialic acids [63;64]. Lse is believed to participate in the de-O-acetylation of 9-O-
acetylated sialoglycoconjugates in the lysosomal compartment. However, it cannot access free 
O-acetylated sialic acids present in the cytosol, which are poor substrates for CMP-sialic acid 
synthase [65] and sialate-pyruvate-lyase [66]. Additionally, CMP-linked O-acetylated sialic 
acids are poor substrates for sialyltransferases [67]. Therefore, Cse has been proposed to act 
on the cytosolic pool of free 9-O-acetylated sialic acids. In this respect, it is interesting to note 
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that the Cse activity is very high in rat brain [53], where 9-O-acetylated sialic acids are 
commonly expressed. 
 
1.2.3.3  Regulation of the Expression of O-Acetylated Sialic Acids  
A great deal of evidence suggests that the expression of O-acetylated sialic acids is growth-, 
species-, tissue-, and molecule-specific [2], indicating that a complex combination of different 
factors is involved in regulating the expression of O-acetylated sialic acids on 
glycoconjugates. These factors might include the regulation of OATs expression, the control 
of substrate synthesis and transport, as well as the control of O-acetylated sialic acids 
degradation. 
    The expression of OAT gene might be regulated during cell differentiation [41;68], 
development [69] and in diseased cells [7]. However, the factors controlling the gene 
expression and the regulation of enzyme activities in vivo are still challenges for future 
research, since these enzymes have proven difficult to be purified or cloned [70]. 
    Investigations on 7(9)-OATs point out the existence of a family of 7(9)-OATs having 
different substrate affinities [4]. It has been found that O-acetylation can be specific for 
particular types of glycoconjugates in a given cell type. For example, OAT from rat liver 
seems to be specific for Neu5Ac present on N-glycans [71], while that from human melanoma 
is specific for gangliosides [72]. Therefore, the activity of OAT could be regulated at the 
substrate level, that is, the availability of an appropriate substrate can influence the activity of 
OAT in a given cell type [41]. Actually, it was observed that the polyoma T antigen-positive 
Chinese hamster ovary cells (CHO-Tag cells), which do not express cell-surface 9-O-
acetylation, could express O-acetylated sialic acids when transiently transfected with a cDNA 
encoding lactosamine-specific α2,6-sialyltransferase (Galβ4GlcNAc:α2,6-sialyltransferase, 
ST6Gal I) [41]. 
    The AcCoA present in the cytosol must be transported into the Golgi apparatus in order to 
act as the donor substrate for OATs [36;37]. A specific transport system has been proposed to 
regulate the supply of AcCoA [36]. Till now, the underlying mechanism of the transport of 
AcCoA has not been clarified. 
    The expression of O-acetylated sialic acids could further be regulated by OAEs. That is, the 
selective and specific distribution of OAEs could be another potential regulatory point. It has 
been demonstrated that the distribution of Lse mRNA is both spatially and temporally 
regulated during murine development [73]. In mouse adult tissues, the differential expression 
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of mRNAs for Lse and Cse was observed [63;64]. Additionally, large molecules such as cell 
surface mucins could play as a regulatory factor by masking some O-acetylated 
gangliosides [74], and thus hindering OAE activities. 
 
1.2.4  Sialidase  
Sialidases (EC 3.2.1.18) are classified into two groups according to their site of cleavage. 
Exo-sialidase hydrolyzes the O-glycosidic linkages between the terminal sialic acids and the 
subterminal monosaccharides of free and glycoconjugate-bound oligosaccharides, while 
endo-sialidase hydrolyzes the internal sialic acid glycosidic bonds of oligo- or polysialyl 
chains [2]. Most microbial and animal sialidases belong to the first group, and are usually 
simply referred to as “sialidase” [2]. 
 
1.2.5  Sialate-Pyruvate-Lyase  
Sialic acids released by sialidases are degraded by a cytosolic sialate-pyruvate-lyase (EC 
4.1.3.3), yielding acylmannosamines and pyruvate. Figure 1-3 shows the structural elements 
of sialic acids required for sialate-pyruvate-lyase recognition [66;75]. 
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Figure 1-3 Sialic Acid Structural Features Required for Interaction with Sialate-Pyruvate-
Lyase [75]. 
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1.3  Methods for Studying Sialic Acids 
For accurate analysis, sialic acids from biological sources must be released and purified 
without the loss of their modification. Practically, this is a severe problem when analyzing 
glycosidically linked O-acetylated sialic acids. Enzymatic hydrolysis using sialidase cannot 
completely release O-acetylated sialic acids, while 4-O-acetylated sialic acids are resistant to 
the action of sialidases with the exception of some viral sialidases [2]. In contrast, mild acid 
hydrolysis can release almost all kinds of sialic acids, however, a significant proportion of O-
acetyl groups is lost [76]. 
    Once released and purified, sialic acids can be analyzed by colorimetry, TLC (thin-layer 
chromatography), GLC (gas-liquid chromatography), MS (mass spectrometry) and NMR 
(nuclear magnetic resonance spectrometry) [2;8]. The technique of derivatization with DMB 
followed by HPLC analysis with fluorescent detection has proven to be particularly sensitive, 
specific, and applicable to most sialic acids [77]. Monoclonal antibodies and lectins have also 
been used to identify O-acetylated sialic acids [2;7;8]. A recombinant soluble form of the 9-
O-acetyl-specific hemagglutinin of influenza C virus has been successfully used to probe for 
such molecules in cells and tissues [59;60]. 
 
1.4  Glycosylation Patterns of Human Colonic Mucins 
1.4.1  Structure of Mucin-Type O-Glycan 
Mucins are high molecular weight glycoproteins, which are heavily glycosylated with many 
oligosaccharide side chains, which are O-glycosidically linked to the protein 
backbone [78;79]. Three regions of complex oligosaccharides on mucin-type proteins have 
been arbitrarily assigned: the core region, which comprises the innermost two or three sugars 
of the glycan chain proximal to the peptide, the backbone region, which mainly contributes to 
the lengths of the chains formed by uniform elongation, and the peripheral region, which 
exhibits a high degree of structural complexity and can represent blood group and other 
related carbohydrate antigens [80]. Table 1-2 shows the eight core structures found in mucin-
type O-glycan [78;80]. 
    The pattern of O-linked glycans shows species-, tissue-, cell type-specificity, and could be 
changed in diseases [78;79;81]. The glycan structures of human colonic mucins are 
predominantly based on core 3 structures [82;83], and a multitude of structural alterations of 
O-glycans has been observed in colorectal cancer, including a decrease in total mucin content, 
a decrease of sulfatation and O-acetylation with an increase in sialylation [79;84-86]. 
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Table 1-2 O-Glycan Core Structures. 
 
Core Structure 
1 Galß1-3GalNAcα-Ser/Thr-R 
2 GlcNAcß1-6[Galß1-3]GalNAcα-Ser/Thr-R 
3 GlcNAcß1-3GalNAcα-Ser/Thr-R 
4 GlcNAcß1-6[GlcNAcß1-3]GalNAcα-Ser/Thr-R 
5 GalNAcαGalNAcα-Ser/Thr-R 
6 GlcNAcß1-6GalNAcα-Ser/Thr-R 
7 GalNAcα1-6GalNAcα-Ser/Thr-R 
8 Galα1-3GalNAcα-Ser/Thr-R 
 
 
1.4.2 O-Acetylated Sialic Acids on Human Colonic Mucins and Human 
Colorectal Cancer 
The mucins synthesized and secrected by the human colonic mucosal cells constitute the 
major component of mucus gels that cover the epithelial surfaces of colon [87], and thus 
protect cells and epithelia from the attack by the external environment, including degradative 
enzymes [88], bacteria [89] and mechanical stresses [90]. Membrane-bound mucins may have 
protective functions comparable to secretory mucins, however, they may also play a role in 
mediating cell-cell interactions especially during development and carcinogenesis, as well as 
in cell migration, adhesion and recognition [90;91]. 
    The majority of oligosaccharides in normal colonic mucin contain 4-12 monosaccharides, 
and are highly sialylated and sulfated [82;83;92]. Chemical analyses have shown that more 
than 50 % of colonic mucin sialic acids are O-acetylated, with 30 % containing oligo-O-acetyl 
forms with 2 or 3 acetyl esters per sialic acid residue [93-95]. Histochemical data suggest that 
the total sialate O-acetylation is at least 80 % [96]. This high degree of sialate O-acetylation is 
characteristic for the human colon and has not been detected in other human tissues [95], 
INTRODUCTION 
 12
although a high level of O-acetylated sialic acids has been observed in bovine submandibular 
gland mucins [18]. 
    The occurrence of O-acetylated sialic acids in human colonic tissue is developmentally 
regulated, with the level of sialate O-acetylation strongly increasing after birth [69]. However, 
this level can be quite variable, depending on bacterial products and environmental stimuli 
[69]. Moreover, an ethnic difference in the expression level of O-acetylated sialic acids on 
colonic mucins has been observed between Sino-Japanese and non-Sino-Japanese [97]. The 
occurrence of O-acetylated sialic acids in the latter group (British, Icelanders, South African 
blacks and Bahrainis) is much more frequent than in Chinese and Japanese. This is speculated 
to be due to a single autosomal gene polymorphism, which might be related to a different 
infective environment. 
    The significance of the high expression level of O-acetylated sialic acids is related to the 
degradation of mucins by bacterial enzymes [52]. The presence of ester groups on sialic acids 
can hinder the action of enteric bacterial sialidase [98;99]. However, a sialate-O-
acetylesterase has been detected in individual bacterial strains and in faecal extracts from 
normal individuals [52;100], which can facilitate the action of sialidase by removing O-acetyl 
groups from sialic acids. The lower activity of the esterase relative to sialidase suggests that 
the degradation of mucins could be regulated at the level of sialate O-acetylation [100]. 
    In contrast to melanoma and basalioma [17;101;102], the degree of O-acetylation, 
presumably on O-linked oligosaccharides, in cancerous colonic mucosa appears to be reduced 
in comparison to that normally found in healthy colonic mucosa [93-95;103]. Further studies 
on the carcinoma human colonic cell lines by Corfield et al. (1999) [95] show that di- and tri-
O-acetylated sialic acids are diminished at the early stage of malignant transformation, while 
a significant proportion of mono-O-acetyl sialic acid remains constant in the range of 10-15 % 
of membrane sialic acids. These observations raise many questions concerning the occurrence 
and enzymatic processes involved into the O-acetylation and de-O-acetylation of sialic acids 
in human colon. 
 
1.5  Objective of this Project 
The majority of our knowledge concerning the O-acetylation of sialic acids in mammals has 
been obtained from the investigations using bovine submandibular glands and rat liver, 
however, these enzymes have not been purified to homogeneity or cloned. This requires 
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further investigation to obtain much more kowledge about the sialate O-acetylation in 
different systems. 
    The high level of O-acetylated sialic acids in human colonic tissues makes this tissue to be 
a good material for the investigation of enzymatic sialate O-acetylation, which is not yet well 
understood. Therefore, one of the main aims of this project is to demonstrate the enzyme 
activity in human colonic mucosa, find the enzyme acceptor substrate, confirm the nature of 
enzyme products, and determine the kinetic parameters. On this basis, attempts would be 
made to solubilize the membrane enzyme in an active form and, if successful, further 
purification of the enzyme would be performed. Another main point of this project is to work 
out the pathway of enzymatic sialate O-acetylation in human colonic mucosa. 
    Moreover, the reduction of O-acetylated sialic acids has been observed to be an early event 
during the maliganant transformation in human colorectal cancer, however, the underlying 
mechanism is not clear. It is supposed that changing of the activities of OAT and OAE could 
occur in cancerous tissues, thus, the comparative investigation of the activitites of these two 
enzymes in the uninvolved and cancerous colonic mucosa will be performed. This 
investigation can shed light on the regulation of O-acetylation of sialic acids at the 
biochemical level in human colonic mucosa as well as on the possible mechanism for the 
decrease in the O-acetylated sialic acids level in cancerous tissues.  
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2  Materials and Methods 
2.1  Materials 
2.1.2  Chemicals and Enzymes 
Chemicals Company 
[3H]AcCoA Moravek Biochemicals, Ca. USA 
AcCoA, trilithiumsalt Sigma, Deisenhofen 
Acetic acid, 100 % Merck, Darmstadt 
Acetic anhydride Riedel de Haßn 
Acetic acid kit Boehringer, Mannheim 
Asialofetuin Sigma, Deisenhofen 
4-(2-amionethyl)-benzolsulfonylchloride-
hydrochloride (Pefabloc) 
Boehringer, Mannheim 
Ammonia, 25 %  Merck, Darmstadt 
Ammonium acetate  Merck, Darmstadt 
BCA protein kit Pierce, Illinois, USA 
n-Butanol Riedel de Haßn 
Bovine serum albumin Boehringer, Mannheim 
Cacodylate sodium Merck, Darmstadt 
Calcium chloride Fluka, Buchs, Schweiz 
CHAPS Biomol, Hamburg 
p-Chloromercuribenzoate Sigma, Deisenhofen 
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Chemicals Company 
Chloroform Merck, Darmstadt 
Cytidine 5'-monophosphate, disodium salt Sigma, Deisenhofen 
CMP-[4,5,6,7,8,9-14C]Neu5Ac Amersham, Braunschweig, Germany 
CMP-Neu5Ac Calbiochem-Novabiochem, Bad 
Soden 
CoA, trilithiumsalt ICN, Aurora, Ohio, USA 
Complete TM Roche, Mannheim, Germany 
Diethylpyrocarbonate Applichem, Darmstadt 
4,4'-Diisothiocyanostilbene-2,2'-disulfonic 
acid disodium salt (DIDS) 
Sigma, Deisenhofen 
Dipotassium phosphate Merck, Darmstadt 
Dithiothreitol  Biomol, Hamburg 
DMB Dojindo Laboratories, Tokyo, Japan 
or Fluka, Buchs, Schweiz 
Edible bird nest substance Mect. Co., Tokyo, Japan 
Ethylenediaminetetraacetic acid, 
tetrasodium salt  
Sigma, Deisenhofen 
Ethanol  Merck, Darmstadt 
Formic acid Merck, Darmstadt 
Fetuin  ICN, Aurora, Ohio, USA 
Galactose-MU Sigma, Deisenhofen 
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Chemicals Company 
5-Fluoro-2',3’-isopropylidene-5'-O-(4-N-cetyl-
2,4-dideoxy-3,6,7,8-tetra-O-acetyl-1-
methoxycarbonyl-D-glycero-alpha-D-
galactooctapyranosyl)uridine (KI-8110) 
Mect Corporation, Tokyo, Japan 
Glycerol Merck, Darmstadt 
GD3 Biomol, Hamburg 
Human colonic mucin Kindly presented by Prof. Dr. K. 
Ishihara, Kitasato University, 
Sagamihara, Japan 
Lecithin  Sigma, Deisenhofen 
LUBROL Px Sigma, Deisenhofen 
Methanol Merck, Darmstadt 
MgCl2 Merck, Darmstadt 
Monopotassium phosphate Merck, Darmstadt 
Monoclonal antibody for 9-O-acetylated GD3 Kindly presented by Mr. S. Toshiaki, 
Snow Brand Milk Products Co. Ltd., 
Kawagoe, Japan 
Methylumbelliferon Sigma, Deisenhofen 
4-Methylumbelliferyl acetate Sigma, Deisenhofen 
Nitroblautetrazoliumchlorid /5-Brom-4-chlor-
3-indolyl-phosphate (NBT/BCIP stock 
solution) 
Boehringer, Mannheim 
Neu2en5Ac Boehringer, Mannheim 
  
MATERIALS AND METHODS 
 17
Chemicals Company 
Neu5Ac Snow Brand Milk Products Co. Ltd., 
Kawagoe, Japan  
Nonidet P 40 Fluka, Buchs, Schewiz 
9-O-Acetylated GD3 Prof. Bernhard Kniep, Institut für 
Immunologie, Medizinische Fakultät, 
"Carl Gustav Carus" Universität, 
Dresden 
1-O-Octyl-ß-D-glucopyranoside Fluka, Buchs, Schewiz 
Orcinol  Fluka, Buchs, Schewiz 
Perchloroacetic acid, 37 % Merck, Darmstadt 
Pefabloc SC  Roche, Germany. 
n-Propanol BASF, Ludwigshafen 
Potassium chloride Merck, Darmstadt 
Propionic acid, 99 % Merck, Darmstadt 
Pyridine  Merck, Darmstadt 
Saponin  Sigma, Deisenhofen 
α2,6-Sialyltransferase, rat liver Sigma, Deisenhofen 
Sialate-pyruvate-lyase Sigma, Deisenhofen 
Sodium hydroxide  Merck, Darmstadt 
Sucrose Carl Roth GmbH, Karlsruhe 
Tris (hydroxymethyl)aminomethane, ultra pure ICN, Aurora, Ohio, USA 
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Chemicals Company 
Triton X-100 Sigma, Deisenhofen 
Trichloroacetic acid Merck, Darmstadt 
Trypsin Sigma, Deisenhofen 
Tween 20 Sigma, Deisenhofen 
Zwittergent 3-12 Fluka, Buchs, Schewiz 
 
2.1.2  Materials for Chromatography 
Chemicals Company 
Methanol for HPLC Promochem, Wesel 
Acetonitrile for HPLC Promochem, Wesel 
Dowex 2 x 8, 200-400 mesh Fluka, Buchs, Schweiz 
Dowex 50W x 8, 20-50 mesh Fluka, Buchs, Schweiz 
DC-Cellulose plate, 20 x 20 cm Merck, Darmstadt 
DEAE-Sepharose FF Pharmacia, Freiburg 
HPTLC silica gel 60 plate, 10 x 20 cm Merck, Darmstadt 
RP-18 cartridge column Merck, Darmstadt 
 
 
2.1.3  Biological Materials 
Human colonic tissues were prepared freshly from patients who underwent surgical resection 
of colorectal carcinoma. Each patient was informed about the study and gave written consent 
in accordance with the ethical guidelines of the Christian-Albrechts-University (CAU), Kiel.  
    Fresh “uninvolved” colonic mucosa was obtained from the excised end of colonic tissue 
resected for carcinoma, and was found to be histologically normal. For the comparative study, 
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the cancerous mucosa, containing at least 80 % cancer cells, was also prepared from the same 
patient. The cancer stage assessment, based on the TNM classification system [104], was 
made by routine clinical and histological methods. Of the 12 tumor samples obtained, 5 were 
at stage 2, 5 were at stage 3 and 2 were at stage 4. The dissected mucosa was washed in PBS 
and frozen at -80 °C until required.  
    Two non-malignant human colonic epithelium cell lines (csc-das1 and ncm-das 460) were 
kindly provided by Professor Dr. H. Kalthoff (Klinik für Allgemeine Chirurgie und 
Thoraxchirurige, Christian-Albrechts-Universität zu Kiel, Germany) 
 
2.1.4  Instruments and Other Materials 
Instruments and Materials Company 
Centrex UF-0.5 and UF-2 Schleicher & Schuell, Dassel 
Dialysis Tube Sartorius AG, Göttigen 
Eppendorf Thermostat 5320 Eppendorf, Hamburg 
Fluorolite    Dynatech Lab., Inc. Chantilly, VA 
HPLC System Merck-Hitachi, Darmstadt 
J2-HS Centrifuge Beckman, München 
Lyophilizer alpha 1-4 Bachofer, Reutlingen 
Microplate  Sarstedt, Nümbrecht 
Microplate Photometer, Titertek Multiscan-
MC 
Flow Laboratories, Uxbridge, U.K. 
Mini-Potter Homogenizer Walter Ebel, Hamburg 
Quartz Cuvette, 1 mL  Hellma, Müllheim 
U-2000 Spectrophotometer Hitachi, Japan 
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Instruments and Materials Company 
Speed Vacuum, SC 110 Bachofer, Reutlingen 
Sunrise, Microplate Photometer TECAN, Crailsherim, Germany 
TLC-Linear Analyzer LB 284  Berthold, Wildbad, Germany 
Ultracentrifuge L7-65 Beckman, München 
Ultraturrax IKA T25 Jahnke & Kunkel, Stufen 
Ultrasonic Processor    Walter F.C. EBEL, Hamburg, 
   Germany 
 
 
2.2  Methods 
2.2.1  Preparation of Subcellular Fractions from Human Colonic Mucosa 
2.2.1.1  Preparation of Microsomes from Human Colonic Mucosa 
All procedures were carried out at 4 °C unless otherwise stated. The mucosa was 
homogenized in 10 mM Tris-HCl buffer, pH 7.4, using an Ultraturrax at maximal speed (3 
times 10 s with a 30 s pause on ice between each burst) and centrifuged at 10 000 x g for 
15 min. The supernatant (crude homogenate) was centrifuged at 100 000 x g for 60 min. The 
resulting supernatant (cytosolic fraction) was stored at -80 °C until required. The resulting 
pellet was re-homogenized with a mini Potter homogenizer in the same buffer and centrifuged 
again at 100 000 x g for 60 min. The pellet was re-suspended in PK buffer (50 mM phosphate 
buffer, pH 7.0), containing 50 mM KCl, and referred to as the microsomal fraction. 
 
2.2.1.2 Simultaneous Preparation of Microsomes and Lysosomes for Sialate-O-
Acetylesterase Assay  
Lysosomes and microsomes were prepared from human colonic mucosa using the method 
described in Butor et al. (1993) [71]. Briefly, the mucosa was homogenized in 10 mM Tris-
HCl buffer, pH 7.45, containing 0.25 M sucrose as described above. Following centrifugation 
at 3 000 x g for 15 min, the supernatant (referred to as homogenate) was removed and further 
centrifuged at 11 000 x g for 30 min. The pellet (post 11 000 x g pellet) was saved for the 
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preparation of lysosomes, while the resulting supernatant was centrifuged at 100 000 x g for 
60 min. The pellet and supernatant obtained were referred to as microsome and cytosol, 
respectively. 
    The post 11 000 x g pellet was re-suspended in 0.025 M sucrose (1 mL/g of mucosa) and 
allowed to swell for 30 min on ice. The supernatant obtained after centrifugation at 11 000 x g 
for 20 min was removed and set aside, while the pellet was re-suspended in 0.025 M sucrose 
containing 0.02 M KCl (0.5 mL/g of mucosa) and again centrifuged at 11 000 x g for 30 min. 
The supernatants were pooled (crude lysosomal fraction) and used for esterase assay. 
    A total membrane fraction was also prepared from the homogenate through centrifugation 
at 100 000 x g for 30 min. The resulting pellet, which contained all membrane components, 
was surfaced washed, re-suspended in PK buffer containing 50 mM KCl, and stored at -80 °C 
until required. 
 
2.2.1.3  Preparation of Golgi Vesicles from Human Colonic Mucosa 
Procedure 1: Subcellular membrane fractions were isolated from human colonic mucosa 
using a modification of the discontinuous sucrose density gradient method described by 
Lepers et al. (1989) [21]. Briefly, 10 g of human colonic mucosa was homogenized in 30 mL 
of ice-cold homogenizing buffer (10 mM Tris-HCl buffer, containing 5 mM MgCl2, pH 7.4) 
containing 0.25 M sucrose, using an Ultraturrax at intermediate speed (3 times 10 s with 30 s 
pause on ice between each burst). Following centrifugation at 600 x g for 15 min, the 
resulting supernatant was adjusted to 1.4 M sucrose by the addition of 2 M sucrose. All 
sucrose solutions were prepared in the homogenizing buffer. Ten mL of the 1.4 M sucrose 
supernatant fraction was layered over a discontinuous sucrose gradient consisting of 5 mL of 
1.6 M sucrose, 9 mL of 1.2 M sucrose and 9 mL of 0.8 M sucrose in a Beckman SW 28 
centrifuge tube. After centrifugation at 100 000 x g for 2 h, the turbid bands at different 
sucrose interfaces were collected, diluted to 0.25 M sucrose with homogenizing buffer and 
collected by centrifugation at 100 000 x g for 30 min. The resulting pellet was re-suspended 
in PK buffer containing 50 mM KCl and 0.25 M sucrose, aliquoted and stored at -80 °C until 
required. The fraction collected from the 0.8 M/1.2 M interfaces represented the Golgi-
enriched fraction (fraction A). Fractions collected from the 1.2 M/1.4 M and the 1.4 M/1.6 M 
interfaces, as well as the pellet, were referred to as fractions B, C and D, respectively. 
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Procedure 2: Golgi vesicles were prepared by a modification of the method described in 
Sjoberg et al. (1993) [38]. All sucrose solutions were prepared in 25 mM of phosphate buffer, 
pH 7.0. Human colonic mucosa was homogenized in 3 volumes of 0.25 M sucrose using an 
Ultraturrax as described above, and centrifuged at 500 x g for 15 min. The supernatant was 
adjusted to 1.2 M sucrose using a 2 M sucrose solution, of which 18 mL was placed in a 
35 mL ultracentrifuge tube. The 1.2 M suspension was overlaid with 10 mL of 1.1 M sucrose 
followed by 7 mL of 0.25 M sucrose. The membrane fraction removed from the 0.25-1.1 M 
interface following centrifugation at 85 000 x g for 90 min was adjusted to 0.25 M sucrose 
and pelleted at 100 000 x g for 30 min. The pellet was resuspended in PK buffer containing 
50 mM KCl and 0.25 M sucrose, aliquoted, and stored at – 80 °C until required. 
 
Procedure 3: Subcellular membrane fractions were isolated from human colonic mucosa 
using the discontinuous Ficoll density gradient method described by Vandamme-Feldhaus and 
Schauer (1998) [35]. Human colonic mucosa was homogenized in 1.5 volumes of 100 mM 
Tris-HCl buffer, pH 7.4, using an Ultraturrax and adjusted to 1.5 % Ficoll by the addition of 
3 % Ficoll solution containing protease inhibitors. All the Ficoll solutions were prepared in 
100 mM Tris-HCl buffer, pH 7.4. After centrifugation at 600 x g for 15 min, the supernatant 
was laid over a discontinuous Ficoll gradient consisting of 10.8 mL of 19 % Ficoll, and 
5.4 mL each of 17 %, 15 %, 9 % Ficoll in a SW 28 ultracentrifugation tube. Following 
centrifugation at 100 000 x g for 30 min, the membrane fractions at different Ficoll interfaces 
were collected, diluted 10 times with 10 mM Tris-HCl buffer, pH 7.4, and pelleted 
(100 000 x g for 30 min). The resulting pellet was re-suspended in PK buffer containing 
50 mM KCl and 0.25 M sucrose, aliquoted, and stored at – 80 °C until required. 
 
Procedure 4: The sucrose-CsCl density gradient method described by Sandberg et al. 
(1980) [105] and Yusuf et al. (1983) [106] was adapted for the preparation of Golgi vesicles 
from human colonic mucosa. All sucrose-CsCl solutions were in PK buffer containing 50 mM 
KCl. Briefly, human colonic mucosa was homogenized in 3 volumes of ice-cold 0.3 M 
sucrose using an Ultraturrax and centrifuged at 10 000 x g for 15 min. The post-nuclear 
supernatant was mixed with 2 M sucrose and 1 M CsCl to a final concentration of 1.05 M and 
10 mM, respectively. The sucrose-CsCl gradient was prepared by layering 5 mL of 1.0 M 
sucrose and 7 mL of 0.3 M sucrose over 25 mL of the 1.05 M sucrose/10 mM CsCl 
suspension. After centrifugation at 100 000 x g for 3 h, the Golgi-enriched fraction was 
collected from the 0.3-1.0 M interface, diluted with 10 mM Tris-HCl buffer and pelleted 
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(100 000 x g for 30 min). Pellets obtained were re-suspended in PK buffer containing 50 mM 
KCl and 0.25 M sucrose,  aliquoted, and stored at – 80 °C until needed. 
 
2.2.1.4 Preparation of the Cytosolic and Membrane Fractions from Human Colonic 
Cell Line 
The method described in Vavasseur et al. (1994) [107] was adopted to prepare the cytosolic 
and membrane fractions. In short, the cell pellets were treated with sonication (Power setting 
20, 3 times 15 second) in 250 µL of PK buffer containing 50 mM KCl. After centrifugation at 
600 x g for 15min, the resulting supernatant (referred as homogenate) was further centrifuged 
at 100 000 x g for 30min. The resulting supernatant (cytosolic fraction) and the pellet 
(membrane fraction) as well as the homogenate were immediately used for 7(9)-OAT assay.  
 
2.2.2  Protein Determination 
Protein concentration was measured using the Micro-BCA protein assay reagent kit as 
described by the manufacturer. 
 
2.2.3  Marker Enzyme Assay 
2.2.3.1  ß-Galactosidase 
The lysosomal marker, ß-galactosidase, was assayed by an adaptation of the method described 
in Lo et al. (1979) [108]. The reaction mixture, consisting of 50 mM sodium acetate (pH 4.6), 
0.556 mM MU-Gal and varying amounts of protein in a final volume of 100 µL, was 
incubated at 37 °C for 30 min. The reaction was stopped by the addition of 600 µL of 0.5 M 
glycine (pH 10.2) and the fluorescence measured at excitation 365 nm and emission 400 nm 
on a Fluorescence Spectrophotometer (Dynatech Laboratories Inc.). The amount of MU 
released was determined from a MU standard curve (0-10 nmol). One unit of enzyme activity 
equals 1 nmol of MU released from MU-Gal per minute under the condition used. 
 
2.2.3.2  Sialyltransferase Assay Using Asialofetuin as Acceptor Substrate 
Sialyltransferase (ST) activity, a marker for the Golgi apparatus, was determined using the 
method described by Alhadeff and Holzinger (1979) [84] with slight modifications. In brief, 
the reaction mixture containing, in a final volume of 200 µL, 50 µg of membrane protein, 
50 mM Tris-HCl buffer, pH 7.4, 10 mM MgCl2, 200 µg asialofetuin, 1 % Triton X-100, and 
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CMP-[14C]Neu5Ac (0.025-0.01 µCi, 5 nmol) was incubated at 37° C for between 30 to 
60 min. The reaction was terminated by the addition of 800 µL ice-cold 5 % PCA to a final 
concentration of 4 %. The precipitates, following a 30 min incubation on ice, were collected 
by centrifugation at 14 000 rpm for 30 min. The resulting supernatant was removed, and the 
pellet was re-suspended in 200 µL of ice-cold water with brief sonication. Following re-
centrifugation at 14 000 rpm for 30 min, the pellet was dissolved in 400 µL of 1 M NaOH by 
heating at 80 °C for 15 min. The dissolved material was then neutralized with 200 µL of 2 M 
HCl and 550 µL of this mixture was used to determine the incorporated radioactivity by 
scintillation counting. One unit of ST activity is defined as the amount of enzyme that will 
transfer 1 nmol of Neu5Ac from CMP-Neu5Ac to asialofetuin per hour under the condition 
used. 
    The latency of ST activity against asialofetuin was determined in the presence and absence 
of 0.5 % (v/v) of Triton X-100. 
 
2.2.4  Sialic Acid Analysis 
2.2.4.1  Acid Release of Glycoconjugate-bound Sialic Acids  
Glycoconjugate-bound sialic acids were released with 2 M propionic acid at 80 °C for 2.5-
4 h [76]. Following acid hydrolysis, sialic acids were collected by ultrafiltration (Centrex UF-
0.5, 3 K MWCO) and purified as described below. 
    Free sialic acids were directly collected by ultrafiltration (Centrex UF-0.5, 3 K MWCO), 
lyophilized and purified. 
 
2.2.4.2  Sialic Acid Purification 
For the purpose of GC-MS analysis, sialic acids were purified by sequential ion exchange 
chromatography as described by Reuter and Schauer (1994) [109]. Acid-released sialic acids 
were applied to a column of the cation exchanger Dowex 50 W X 8 (20-50 mesh, H+ form) 
and eluted with 5-10 column volumes of water. The eluate was then applied to a column of 
the anion exchanger Dowex 2 X 8 (200-400 mesh, HCOO- form). After washing the column 
with 5-10 column volumes of ice-cold water, sialic acids were eluted with 10 column volumes 
of 0.8 M HCOOH. The eluate was lyophilized and stored at –20 °C until analyzed. 
    For other purposes, sialic acids were purified on a column of Dowex 2 X 8 as described 
above. 
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2.2.4.3  Quantitation of Sialic Acids 
Quantitation of sialic acids was carried out by a micro-adaptation of the Oricinol/Fe3+/HCl 
assay (BIAL-test) described in Reuter and Schauer (1994) [109]. Briefly, 100 µL of sample 
solution, containing up to 8 µg/µL sialic acids, was thoroughly mixed with 100 µL of BIAL 
reagent, and incubated at 95 °C for 15 min. After cooling on ice for 5 min, 700 µL of 
isoamylalcohol was added and the mixture was thoroughly vortexed. The absorbance of the 
upper organic phase, following centrifugation at 14 000 rpm for 15 min, was measured 
spectrophotometerically at 572 nm. 
 
2.2.4.4  Saponification of O-Acetylated Sialic Acids 
Sialic acids were incubated with 100 µL of 100 mM NaOH at 37 °C for 30 min, and the 
mixture was neutralized with an equal volume of 100 mM HCl. Alternatively, sialic acid 
samples were mixed with 5 volumes of 4 M NH3 and incubated for 4 h at room temperature. 
The NH3 was removed by lyophilization using a Speed Vacuum. 
 
2.2.4.5  Sialate-9-O-Acetylesterase Treatment  
Fifteen µL of purified sialic acids was mixed with 25 µL of PBS (pH 7.0) and incubated with 
15 µL of influenza C/JJ/50 virus at 37 °C for 1 h. The reaction was stopped by heating at 
95 °C for 3 min, following which the suspension was cooled on ice for 5 min. After 
centrifugation at 14 000 rpm for 30 min, the supernatant was removed and analyzed by 
scintillation counting, as well as radio-HPLC. 
 
2.2.4.6  Sialate-Pyruvate-Lyase Treatment  
Purified sialic acids were incubated with 25 mU of sialate-pyruvate-lyase in 100 µL of PK 
buffer at 37 °C for 2 hour. The reaction was terminated by heating at 95 °C for 5 min and 
cooled on ice for 5 min. After centrifugation at 14 000 rpm for 30 min, the supernatant was 
removed and analyzed by scintillation counting, as well as radio-HPLC. 
 
2.2.4.7  Fluorometric HPLC Analysis of Sialic Acids 
Purified sialic acids were derivatized with DMB reagent (56 °C for 1 h, in the dark) and 
analyzed by fluorometric HPLC using the method described by Hara et al. (1989) [77]. A RP-
18 cartridge column was eluted in the isocratic mode with methanol-acetonitrile-water 
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(7:9:84, by volume) at 1 mL/min. The retention times of the various sialic acids detected by 
HPLC were compared with authentic sialic acid standards prepared from bovine 
submandibular gland mucins. 
 
2.2.4.8  Preparation of Sialic Acids from Human Colonic Cell Lines 
Two human colonic cell lines were grown in RPMI medium supplemented with 10 % FCS 
containing 2 g/L NaHCO3. Cells were harvested by centrifugation when confluent, washed 
twice with PBS, and detached with a cell scraper. The cell pellets were re-suspended in 2 M 
propionic acid and incubated at 80 °C for 4 h. Following extensive dialysis against distilled 
water (overnight at 4 °C), the released sialic acids were purified and used for fluorometric 
HPLC analysis as described above. 
 
2.2.4.9  Gas Chromatography-Mass Spectrometry 
Purified sialic acids were converted to their pertrimethylsilylated ester/ether derivatives and 
applied to a GC-system coupled with EI-MS and analyzed according to a fragmentation 
scheme by Kamerling et al. (1975) [110]. Professor Dr. J.P. Kamerling and Dr. G. J. Gerwig 
from The Bijvoet Center for Biomolecular Research, Department of Bio-Organic Chemistry, 
Utrecht, and The Netherlands, kindly performed these analyses. 
 
2.2.5  Acetyl-CoA: Sialate-7(9)-O-Acetyltransferase (7(9)-OAT) Assay 
2.2.5.1  Assay for Membrane-Bound 7(9)-OAT 
Assay 1: Utilizing Endogenous Substrates, or Edible Bird Nest Substance (EBNS) as well as 
De-O-Acetylated Human Colonic Mucins (HCM) as Exogenous Acceptor Substrate 
The 7(9)-OAT assay based on endogenous sialic acids present in the protein fractions from 
human colonic mucosa as the acceptor substrate was carried out in 30 µL of PK buffer 
containing 50 mM KCl, protease and esterase inhibitors (CompleteTM and Pefabloc, 
respectively), [3H]AcCoA (0.2 µCi, 8.3 µM) and 50 µg protein, usually at 37 °C for 15 min. 
The reaction was stopped with 60 µL of 3 M propionic acid to yield a final propionic acid 
concentration of 2 M. Glycoconjugate-bound sialic acids were released by incubating at 80 °C 
for 2.5 hours. Following the removal of proteins by centrifugation at 14 000 rpm for 30 min, 
the supernatant was lyophilized. The resulting residue was re-suspended in 200-300 µL of ice-
cold water and applied to a Dowex 2 X 8 column (0.5 mL bed volume, 200-400 mesh, 
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HCOO- form). After washing the column with 5 mL of water, sialic acids were eluted with 
10 mL of 0.8 M formic acid. The eluate was lyophilized and taken up in 15 µL water. One 
third of this sample was used to determine the total incorporated radioactivity by scintillation 
counting. The remaining portion was analyzed by radio-TLC. Following analysis using an 
automatic TLC-linear analyzer LB 284 (Berthold, Wildbad, Germany), the enzyme activity 
was determined by integrating the resulting radioactive peak and correlating this with the 
protein concentration. One unit is defined as the amount of enzyme that will transfer 1.0 pmol 
of acetate from AcCoA to sialic acid per minute at 37 °C, pH 7.0. 
    Enzyme assay utilizing edible bird nest substance (EBNS), containing 96 µg sialic acids, or 
de-O-acetylated human colonic mucin (HCM) as exogenous acceptor substrate was carried 
out as described above. 
 
Assay 2: Utilizing Neu5Ac or CMP-Neu5Ac as Exogenous Acceptor Substrate 
The enzyme assay was carried out in 30 µL of PK buffer containing 50 mM KCl, 600 µM 
Neu5Ac or CMP-Neu5Ac, 50 mM KCl, protease and esterase inhibitors (CompleteTM and 
Pefabloc, respectively), [3H]AcCoA (0.2 µCi, 8.3 µM) and 50 µg microsomal protein, usually 
at 37 °C for 15 min. The reaction was stopped with 60 µL of 3 M propionic acid and heated at 
80 °C for 15 min. After the removal of proteins by centrifugation at 14 000 rpm for 30 min, 
the supernatant was lyophilized. The isolated sialic acids, following purification, were 
analyzed by radio-TLC. 
 
Assay 3: Utilizing α2,3- or α2,6-Sialyllactose as Exogenous Acceptor Substrate 
The enzyme assay utilizing 600 µM of α2,3- or α2,6-sialyllactose, isolated from bovine 
colostrum, as the potential acceptor substrate was performed essentially as described above 
except that the assay was stopped by incubating at 95 °C for 5 min. After centrifugation at 
14 000 rpm, the supernatant was lyophilized and analyzed by radio-TLC. 
 
Assay 4: Utilizing GD3 as Exogenous Acceptor Substrate 
The enzyme assay was performed in 30 µL of PK buffer containing 600 µM GD3, protease 
and esterase inhibitors (CompleteTM and Pefabloc, respectively), [3H]AcCoA (0.2 µCi, 
8.3 µM) and 50 µg microsomal protein, usually at 37 °C for 15 min. The reaction was 
terminated with 120 µL of methanol:chloroform (2:1, by volume). After the removal of 
proteins by centrifugation at 100 000 x g for 15 min, the supernatant was evaporated, re-
supended in 15 µL of methanol:chloroform (2:1, by volume) and analyzed by radio-TLC. 
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2.2.5.2  Assay for Solubilized 7(9)-OAT 
Solubilized proteins from microsomes were incubated with [3H]AcCoA (0.2 µCi, 8.3 µM) and 
600 µM CMP-Neu5Ac in 30 µL of PK buffer containing protease and esterase inhibitors 
(CompleteTM and Pefabloc, respectively). The reaction was initiated with the addition of 
0.8 µL of [3H]AcCoA and incubated at 37 °C for 15 min. After chasing with 0.8 µL of 
AcCoA for another 15 min, the reaction was stopped either with 60 µL of 3 M propionic acid 
to yield a final propionic acid concentration of 2 M, or with ice-cold ethanol (70 % final 
concentration) and incubated on ice for 30 min. The enzyme products were purified as 
described earlier (section 2.2.5.1) and analyzed by radio-TLC. 
 
2.2.6  Confirmation of the Nature of Enzyme Products 
2.2.6.1  Radio-Thin-Layer Chromatography (Radio-TLC) 
The radiolabeled sialic acids released with propionic acid following 7(9)-OAT assays using 
endogenous or exogenous acceptor substrates were applied to TLC plates, either silica gel 60 
HPTLC plates (10 x 10 cm) or cellulose plates (20 x 20 cm), together with authentic 
Neu5,9Ac2 isolated from bovine submandibular glands. Silica gel plates were developed in 
methanol:chloroform:20 mM CaCl2 (5:4:1, by volume) and cellulose plates were developed in 
propanol:butanol:0.1 M HCl (2:1:1, by volume) [109] or EtOH:1 M NH4OAc (7:3, by 
volume, pH 7.3) [111]. 
    Radiolabeled sialyllactose was applied to silica gel 60 HPTLC plates (10 x 10 cm) and 
developed in ethanol:pyridine:water:acetic acid:n-butanol (100:10:10:3:3, by volume) [112]. 
    Radiolabeled GD3, together with authentic 9-O-acetylated GD3, was applied to silica gel 
HPTLC plates which were developed in methanol:chloroform:20 mM CaCl2 (4:5:1, by 
volume) [109]. 
    All radiolabeled sialic acids were detected using an automatic TLC-linear analyzer, and 
their migration distances were compared to those of sialic acid standards stained with 
Fe 3+/orcinol/HCl (BIAL reagent). 
    Saponification of O-acetylated sialic acids was performed by incubating TLC plates 
overnight at room temperature in a tightly sealed chamber saturated with ammonium vapor. 
Plates treated in this manner were thoroughly dried under a stream of cold air and re-analyzed 
by TLC-linear analyzer. 
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2.2.6.2  HPLC Analysis of Radiolabeled O-Acetylated Sialic Acids 
Following the incubation of microsomal fractions with CMP-Neu5Ac as described in section 
2.2.5.1 (Assay 2), the purified sialic acids were divided equally into four aliquots. The first 
aliquot (positive control) was incubated in PBS, pH 7.0 at 37 ºC for 2 hours. The other three 
aliquots were incubated in the presence of 0.1 M NaOH (37 ºC for 30 min), influenza C/JJ/50 
virus and sialate-pyruvate-lyase, respectively, as described previously (section 2.2.4.4-
2.2.4.6). All samples, together with authentic sialic acid standards, were analyzed by 
fluorometric HPLC. The eluates were collected (1 mL/tube) and the radioactivity of each 
fraction was determined by scintillation counting. The nature of the radiolabeled products was 
identified by correlating the elution time to those of the authentic sialic acid standards. 
Negative control was afforded by incubating microsomal proteins with [3H]AcCoA in the 
absence of CMP-Neu5Ac. 
 
2.2.6.3  Separation and Identification of CMP-Neu5,9Ac2 
The separation and identification of CMP-Neu5,9Ac2 as the enzyme product was performed 
using essentially the same enzyme assay, with some modifications, as that described in 
section 2.2.5.1 (Assay 2). The reaction was initiated by the addition of 0.25 µCi [3H]AcCoA. 
After incubation for 15 min at 37 °C, the reaction was chased with 0.8 µL of 0.3 mM AcCoA 
and incubated for a further 15 min. The reaction was terminated by the addition of ice-cold 
ethanol to a final concentration of 90 %. The sample was kept on ice for 1 h, following which 
insoluble materials were removed by centrifugation at 14 000 rpm for 30 min. The 
purification of putative CMP-Neu5,9Ac2 was performed as described by Fritsch et al. 
(1996) [111]. Briefly, the supernatant obtained following centrifugation was lyophilized, re-
suspended in 200 µL of water and applied to a DEAE-Sepharose FF column (0.5 mL bed 
volume, acetate form). The column was then washed with 5 mL of ice-cold water and 
subsequently both the free and CMP-linked sialic acids were eluted with 5 mL of 70 mM 
NH4OAc solution (pH 7.5) followed by a further 5 mL of ice-cold water. The eluate was 
lyophilized, and the residue was taken up in 15 µL of water. This suspension was then 
analyzed by radio-TLC on cellulose TLC-plates in ethanol:1M NH4OAc, pH 7.3 (7:3, by 
volume).  
    Additionally, the incubation was carried out using the same procedure described above 
except that the reaction was stopped by the addition of propionic acid. The enzyme incubation 
performed in the absence of CMP-Neu5Ac was used as a control. 
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2.2.6.4  HPTLC Immuno-Overlay Assay of 9-O-Acetylated GD3 
For HPTLC immuno-overlay assay [113], the enzyme assay was carried out under the same 
condition described in section 2.2.5.1 (Assay 4), except that non-radiolabeled AcCoA was 
used as the donor substrate. The enzyme products, prior to or after saponification, were 
applied to a HPTLC silica gel 60 plate and developed in methanol:chloroform:20 mM CaCl2 
(4:5:1, by volume). After being completely dried under a stream of cold air, the plate was 
plasticized by chromatographing in a freshly prepared hexane solution which was saturated 
with polyisobutylmethacrylate. Following thorough drying, the plate was immersed in PBS 
containing 1 % BSA for 30 min at room temperature. The buffer was decanted and the plate 
was washed twice with PBS. The plate was then overlaid with monoclonal antibody (mAb) 
against 9-O-acetylated GD3, and incubated at 4°C overnight. The unbound antibody was 
washed away in three steps using 0.05 % Tween 20-PBS, each for 5 min under shaking. The 
chromatogram was incubated with an alkaline phosphatase-labeled secondary antibody from 
mouse at a dilution of 1:1000 in 1 % BSA-PBS for 60 min at room temperature and washed as 
above. The plate was visualized with BCIP/NBT reagent as instructed by the manufacturer, 
and the reaction was stopped by rinsing the plate with distilled water and drying.  
 
2.2.7  Factors Influencing 7(9)-OAT Activity 
2.2.7.1  Influences of pH, Temperature, Time and Protein Concentration 
The influences of various factors, including pH, temperature, incubation time and protein 
concentration on 7(9)-OAT activity were investigated using the standard 7(9)-OAT assay 
outlined in section 2.2.5.1. The time, temperature, pH, as well as the protein, substrate and 
inhibitor concentrations are indicated in the figures under section 3.2.8, page 54. 
 
2.2.7.2  Determination of the Apparent KM Values for AcCoA and CMP-Neu5Ac 
The apparent KM for AcCoA was determined using essentially the same procedure as 
described in section 2.2.5.1. Briefly, 50 µg of microsomal protein and 600 µM CMP-Neu5Ac 
were incubated together with different concentrations of AcCoA between 0 and 70 µM under 
optimal conditions (37 °C for 15 min, pH 7.0). 
    The apparent KM for CMP-Neu5Ac was determined as above except that the AcCoA 
concentration was kept constant at 8.3 µM and the concentration CMP-Neu5Ac was varied 
between 0 and 600 µM. The KM values were determined from double-reciprocal plots 
according to the method of Lineweaver-Burk. 
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2.2.7.3  Determination of the Ki Value for CoA 
Fifty µg of microsomal membrane protein was incubated together with different 
concentrations of CoA (0, 10, 15 and 20 µM) at AcCoA concentrations of 8 µM and 16 µM, 
respectively. The enzyme activity was determined as described in section 2.2.5.1 and the Ki 
value was determined using the method described in Dixon et al. (1958) [114]. 
 
2.2.7.4 Influences of Amino Acid-Modifying Reagents and Potential Inhibitors on 
7(9)-OAT Activity 
Utilizing Golgi membrane fractions isolated as described in section 2.2.1.3, page 23. The 
influences of DDT (1 mM), DEPC (2 mM), PCMB (2 mM) and acetic acid anhydride (2 mM 
and 10 mM), as well as saponin (0.005-0.10 %, w/v) on 7(9)-OAT activity were investigated. 
Assays were carried out under optimal conditions (37 °C, pH 7.0 for 15 min) as outlined in 
section 2.2.5.1.  
 
2.2.8  Trypsin Treatment of Golgi Vesicles 
Golgi proteins (3 µg/µL) were treated with trypsin (protein:trypsin=150:1, w/w) in 50 µL of 
20 mM potassium phosphate buffer, pH 7.0, containing 50 mM KCl and 0.25 M sucrose in 
the presence and absence of 0.5 % Triton X-100, at 25 °C for 10 min [115]. The incubation 
was terminated by the addition of three volumes of ice-cold buffer containing 2 mg/mL BSA. 
After centrifugation at 100 000 x g for 30 min, the Golgi vesicles were surface-washed twice 
with 1.5 mL of ice-cold buffer, re-suspended in the original volume of 50 mM Tris-HCl 
buffer, pH 7.45, containing 0.25 M sucrose and immediately used for the determination of ST 
and 7(9)-OAT activity. 
 
2.2.9  Preloading of Golgi Vesicles with CMP-Neu5Ac 
Intact Golgi vesicles were incubated with 500 µM CMP-Neu5Ac in 50 µL of 50 mM Tris-
HCl buffer (pH 7.45), containing 10 mM MgCl2 and protease inhibitor (CompleteTM) at 30 °C 
at time points between 5 min and 30min. Three volumes of the same buffer containing 0.25 M 
sucrose were used to terminate the incubations. These CMP-Neu5Ac-preloaded Golgi 
vesicles were pelleted (100 000 x g for 30 min), surface-washed with ice-cold PK buffer, and 
immediately used in 7(9)-OAT activity assays. 
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    In addition, Golgi vesicles were also preloaded with CMP-Neu5Ac in the presence of 
CMP, CoA, DIDS or KI-8110 under the same condition described above. Golgi vesicles 
preloaded in such a way were referred to as CMP-Neu5Ac-preloaded Golgi vesicles I. 
 
2.2.10  Incubation of CMP-Neu5Ac-Preloaded Golgi Vesicles with [3H]AcCoA 
CMP-Neu5Ac-preloaded Golgi vesicles or CMP-Neu5Ac-preloaded Golgi vesicles I were 
incubated with [3H]AcCoA at 37 °C in 30 µL of PK buffer containing CompleteTM and 
Pefabloc. The reaction was initiated with the addition of 0.8 µL of [3H]AcCoA (0.25 µCi/µL), 
and kept at 37 °C for 15 min. After chasing with 0.8 µL of AcCoA (8.3 µM, final) for another 
15 min at 37 °C, the reaction was stopped by the addition of propionic acid to a concentration 
of 2 M. The acid-soluble fraction was separated from the acid-insoluble fraction via 
centrifugation. Radiolabeled sialic acids were released, purified and analyzed by radio-TLC 
on silica gel plate or cellulose plate. The radioactivity associated with sialic acids was then 
used for the calculation of enzyme activity. 
    Additionally, the incubation of CMP-Neu5Ac-preloaded Golgi vesicles with [3H]AcCoA 
was carried out in the presence of CMP, CoA, DIDS or KI-8110. The enzyme activity was 
determined using the procedure described above. 
 
2.2.11  The Transfer of [3H]Neu5,9Ac2 onto Endogenous Glycoconjugates 
One hundred and fifty µg of intact Golgi vesicles was incubated with [3H]AcCoA and CMP-
Neu5Ac (200 µM) in 30 µL of PK buffer containing 50 mM KCl, protease and esterase 
inhibitors. The reaction was initiated by the addition of 1 µL of [3H]AcCoA (0.25 µCi/µL) 
and incubated at 37 °C for 20 min. Following the addition of 1 µL of non-radiolabeled 
AcCoA to a final concentration of 5.2 µM, the mixture was kept at 37 °C for a further 20 min. 
In order to inhibit the further transport of CMP-Neu5Ac and AcCoA into the Golgi vesicles, 
DIDS was added to a final concentration of 1 mM. The suspension was then further incubated 
at 37 °C between 0 and 4 h, following which the reaction was terminated by the addition of 
propionic acid. 
    For all assays carried out in this manner the acid-soluble and acid-insoluble material was 
separated by centrifugation at 14 000 rpm for 30 min. The resulting pellet was washed three 
times with 500 µL ice-cold water, and the glycosidically linked sialic acids released by 
200 µL 2M propionic acid (80 °C for 4 h) were analyzed by radio-TLC. The acid-soluble 
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material present in the supernatant was lyophilized and also analyzed by radio-TLC on silica 
gel plate. 
 
2.2.12  CMP-[3H]Neu5,9Ac2 as Sialic Acid Donor for STs 
2.2.12.1 Preparation of Asialo-Bovine Submandibular Gland Mucin (Asialo-BSM)  
Ten mg of BSM was hydrolyzed with 7 mL of 0.1 M HCl at 80 °C for 1 h, and was 
extensively dialyzed against distilled water at 4 °C [84]. Analysis of the lyophilized retentates 
for sialic acids content by BIAL-test showed that 60 % of the sialic acids was removed.  
 
2.2.12.2 CMP-[3H]Neu5,9Ac2 as Donor Substrate for STs 
Putative CMP-[3H]Neu5,9Ac2 was prepared using the same procedure described in Section 
2.2.6.3, except that the concentration of the acceptor substrate, CMP-Neu5Ac, was decreased 
to 300 µM. Following purification using DEAE-Sepharose FF, approximately 26 000 dpm of 
putative CMP-[3H]Neu5,9Ac2 was incubated with either 150 µg human colonic Golgi protein 
or 9 mU of rat liver α2,6-ST (EC.2.4.99.1) as described by Sadler et al. (1979) [116]. 
Asialofetuin (200 µg) and asialo-BSM (87 µg) were used as the ST acceptor substrates. 
    The reaction was carried out by incubating the appropriate enzyme with CMP-
[3H]Neu5,9Ac2 in 50 µL of 50 mM sodium cacodylate buffer, pH 6.5, Triton X-100 (0.5 or 
1 %) and 1 mM Pefabloc at 37 °C for 30 to 120 min. When rat liver α2,6-ST was utilized, 
25 µg BSA was added to the mixture. The reaction was terminated by the addition of  TCA to 
a final concentration of 5 %. The radioactivity incorporated into glycoproteins was 
determined using the procedure described in section 2.2.3.2, page 23. 
    ST assays for both human colonic Golgi ST and rat liver α2,6-ST were also performed 
using CMP-[14C]Neu5Ac (0.1 µCi, 10 nmol) as the donor substrate. 
 
2.2.13  Solubilization of Membrane-Bound 7(9)-OAT 
2.2.13.1 Freeze-Thawing 
Microsomes (100 µg) in PK buffer containing 50 mM KCl were frozen at -80 °C and thawed 
at room temperature. Following a second freeze-thawing cycle, the mixture was centrifuged at 
100 000 x g for 30 min. The resulting supernatant (freeze sup) and pellet (freeze pellet) were 
re-suspended in PK buffer, and used for the determination of 7(9)-OAT activity. 
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2.2.13.2 Salt Extraction 
The extraction was carried out according to the procedure described by Mancini et al. 
(1999) [117] with some changes. Two hundred µg of microsomal protein was suspended in 
50 µL of PK buffer containing 1 M KCl. The mixture was incubated at 4 °C for 30 min. After 
centrifugation at 100 000 x g for 30 min, the supernatant was removed and set aside, while the 
pellet (salt pellet) was washed with 50 µL of ice-cold water. The supernatant obtained 
following centrifugation at 14 000 rpm for 15 min was then combined with the previous 
supernatant and desalted by ultrafiltration (Centrex 3 KD). The resulting desalted residue (salt 
sup), as well as the washed pellet, was used in 7(9)-OAT assay. 
 
2.2.13.3 EDTA Extraction 
Microsomal proteins were extracted with EDTA as described in Lachaal et al. (2000) [118]. 
Briefly, 200 µg of microsomal protein was dispersed in 1 mM EDTA (pH 7.5) in a final 
volume of 200 µL and incubated on ice for 30 min. The supernatant (1mM EDTA-sup) and 
pellet (1 mM EDTA-pellet) obtained after centrifugation at 100 000 x g for 30 min were kept 
on ice until required. A portion of the 1 mM EDTA-pellet was re-suspended in 150 µL of 
100 mM EDTA (pH 10.3), immediately centrifuged at 100 000 x g for 30 min, and washed 
with ice-cold water. The resulting pellet and supernatant were referred to as 100 µM EDTA-
pellet and 100 µM EDTA sup, respectively. All the fractions obtained were subsequently used 
for the determination of 7(9)-OAT activity. 
 
2.2.13.4 Detergent Solubilization  
Stock solutions (1-10 %) of the detergents (CHAPS, octylglucoside, Triton X-100, Nonidet 
P40, LUBROL Px and Zwittergent 3-12) were prepared in water. Different volumes of the 
appropriate detergent stock solution were added by stirring to membrane suspensions to give 
detergent/protein ratios that varied between 1:10 and 10:1. Generally, 3-5 mg/mL of total 
membrane protein in PK buffer, containing 50 mM KCl and protease inhibitors was incubated 
with the detergent at 4 °C for 30 min with occasional shaking. The clear supernatant obtained 
following centrifugation at 100 000 x g for 30 min was then used to determine 7(9)-OAT 
activity. 
    In some experiments, solubilization was also performed in the presence of either 1 mM 
DTT, 20 % (v/v) glycerol or 300 µM CMP-Neu5Ac. 
 
MATERIALS AND METHODS 
 35
2.2.13.5 Preparation of Lecithin Stock Solution 
Lecithin stock solution was prepared using the procedure described in Schägger et al. 
(1990) [119]. Eighteen mg of lecithin was dissolved in 250 mM of PK buffer, pH 7.0, 
containing 50 mM KCl and 7.5-9.5 % CHAPS. The molar ratio of CHAPS/lipid is 2-3, which 
is close to the lowest ratio necessary to maintain the lipids in solution. The stock solutions can 
be regarded as lipid-saturated mixed-detergent micelles. 
 
2.2.14  Sialate-O-Acetylesterase Assay 
Assay 1 [55]: MU-Ac was used as the substrate. Esterase assay was carried out at 37 °C for 
10 min in 100 µL of 10 mM Tris-HCl buffer, pH 7.45, containing 200 µM MU-Ac and 5-
10 µg of protein sample. The reaction was terminated by the addition of 100 µL of absolute 
ethanol. The amount of released MU was determined fluorometerically at excitation and 
emission wavelengths of 365 nm and 460 nm, respectively. One unit of enzyme activity 
equals to one nmol of MU released per min under the condition used. 
 
Assay 2 [55]: Free O-acetylated sialic acid (Neu5,9Ac2 or Neu5,7(8),9Ac3) was used as the 
substrate. Esterase assay was carried out in 100 mM Tris-HCl buffer, pH 7.45, at 37 °C for 
15-30 min in the presence of 1 mM of substrate and 50-500 µg of protein. The reaction was 
stopped by heating at 95 °C for 2 min, and centrifuged at 14 000 rpm for 5 min. The amount 
of released acetic acid present in the resulting supernatant was determined using a 
commercially available kit (Boehringer Mannheim, Germany) as instructed by the 
manufacturer. One unit of enzyme activity equals to 1 nmol of acetic acid released from O-
acetylated sialic acid per min under the condition used. In order to confirm the esterase 
activity observed using this assay, the corresponding release of de-O-acetylated sialic acids 
was monitored by HPLC analysis as described in section 2.2.4.7, page 25. 
 
Assay 3: Using BSM as the substrate, esterase assay was carried out essentially as described 
in Assay 2. The substrate concentration was calculated according to the amount of 9-O-
acetylated sialic acids present in BSM, which was determined using the BIAL test and HPLC 
analysis. 
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3  Results 
3.1  Sialic Acid Analysis 
3.1.1  Sialic Acids in Human Colonic Cell Lines 
Due to the heterogeneity and variability of human colonic tissue samples obtained from 
patients who underwent surgical resection of colorectal carcinomas, cell lines derived from 
human colonic epithelium were initially thought to be the most suitable material for the study 
of sialate-O-acetyltransferase. As a basis for investigating the enzymatic reaction/s that 
governs sialate O-acetylation in human colonic mucosa, the nature and quantity of O-
acetylated sialic acids present in the two human colonic cell lines obtained were analyzed. 
    Sialic acids were released from cell pellets by mild acid hydrolysis, purified and analyzed 
by fluorometric HPLC. As shown in Figure 3-1, a significant amount of Neu5Ac (peak 1) was 
observed. A second peak (peak 2) was also observed, which could be oligo-O-acetylated 
Neu5Ac or a reagent peak. Under the condition used, a reagent peak was always found to 
overlap with a peak corresponding to oligo-O-acetylated Neu5Ac. However, the HPLC 
chromatograms, before and after the treatment with NaOH, indicate that no O-acetylated 
sialic acids were expressed in the cell lines tested, because O-acetylated sialic acids treated in 
this manner can be always completely de-O-acetylated, leading to a reduction in the peak 
magnitude and corresponding increase in the amount of Neu5Ac. Therefore, Neu5Ac was the 
only sialic acid detected in the two cell lines investigated. 
    In certain cancerous cell lines derived from primary human colonic adenocarcinomas, O-
acetylated sialic acids were also found not to be present [69]. One reason for this phenomenon 
may be the loss of certain environmental stimuli such as bacterial by-products, which are lost 
due to the sterile and uniform conditions used in tissue culture. Such stimuli might be 
essential for the expression of O-acetylated sialic acids [69]. Moreover, histological analysis 
has shown that O-acetylated sialic acids in normal human colonic tissue are associated with 
sialomucins in the upper half of the crypts in the left colon, and the reverse pattern was 
observed in the right colon [120;121]. Therefore, the selection of cell subpopulations in tissue 
culture could be another reason that no O-acetylated sialic acids were observed in certain cell 
lines. 
    Nevertheless, the activity of 7(9)-OAT in one cell line was assayed using CMP-Neu5Ac as 
acceptor substrate. No enzyme activity was observed in the membrane and cytosolic fractions 
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prepared from the cell pellets as described in section 2.2.1.4, page 23. These results showed 
that these cell lines are not suitable for the study of 7(9)-OAT. 
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Figure 3-1 Fluorometric HPLC Analysis of Sialic Acids in Human Colonic Cell Lines. Two human 
colonic cells lines (A-cell line 1; B-cell line 2) were grown under the condition described under section 2.2.4.8, 
page 26. After harvesting the cells, sialic acids were released by 2 M propionic acid at 80 °C for 4 h. Released 
sialic acids were collected, purified and analyzed by fluorometric HPLC prior to (1) or after (2) saponification. 
Peak 1, Neu5Ac; Peak 2, reagent peak.  
 
3.1.2  Nature of Sialic Acids in Human Colonic Mucosa 
The nature of sialic acids in different subcellular fractions isolated from human colonic 
mucosa was investigated by fluorometric HPLC. Glycoconjugate-bound sialic acids were 
released by mild acid hydrolysis, collected, purified by anion-exchange chromatography and 
analyzed as described in section 2.2.4, page 24. 
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Figure 3-2 Nature of Sialic Acids in the Membrane Fraction from Human Colonic Mucosa. 
Glycoconjugate-bound sialic acids in the membrane fraction were released with 2 M propionic acid (80 °C for 
4 h), collected via ultrafiltration to minimize the loss of O-acetyl groups, purified and analyzed by fluorometric 
HPLC. A, before saponification with 0.1 M NaOH; B, after saponification with 0.1 M NaOH and C, after 
treatment with sialate-pyruvate-lyase. Peak 1, Neu5Ac; Peak 2, Neu5,7Ac2; Peak 3, Neu5,9Ac2; Peak 4, oligo-O-
acetylated sialic acids/reagent peak. 
 
 
    As can be seen in Figure 3-2A, the sialic acids present in the membrane fraction included 
Neu5Ac, Neu5,9Ac2 and oligo-O-acetylated sialic acids, as well as a small amount of 
Neu5,7Ac2. No Neu5Gc was detected in the uninvolved colonic mucosa. Treatment with 
0.1 M NaOH (Figure 3-2B), which can result in the complete de-O-acetylation of sialic acids, 
led to the total saponification of the three peaks corresponding to mono- and oligo-O-
acetylated Neu5Ac (the latter overlaps with a reagent peak which is not affected by alkaline 
treatment) with a concomitant increase in Neu5Ac. The incubation of isolated sialic acids 
with sialate-pyruvate-lyase led to the significant degradation of mono-O-acetylated Neu5Ac 
and Neu5Ac, however, oligo-O-acetylated Neu5Ac was only partially degraded (Figure 3-
2C). The extent to which oligo-O-acetylated Neu5Ac was degraded by sialate-pyruvate-lyase 
could not be conclusively shown since, as stated above, this peak overlaps with a reagent 
peak. Additional experiments have shown that oligo-O-acetylation of sialic acids hinders the 
action of sialate-pyruvate-lyase. The similar pattern of sialic acids, for both glycosidically 
linked (Figure 3-3A) or free (Figure 3-3B), was also found in the cytosolic fraction.  
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Figure 3-3 Nature of Sialic Acids in the Cytosolic Fraction from Human Colonic Mucosa. 
Glycosidically linked sialic acids in the cytosolic fraction (A) were released with 2 M propionic acid (80 °C for 
4 h) and collected, while free sialic acids (B) in the cytosolic fraction were directly collected. The sialic acids 
were purified and analyzed by fluorometric HPLC. Peak 1, Neu5Ac; Peak 2, Neu5,7Ac2; Peak 3, Neu5,9Ac2; 
Peak 4, oligo-O-acetylated sialic acids/reagent peak. 
 
3.1.3  GC-MS Confirmation of Sialic Acids Present in Human Colonic Mucosa 
To directly confirm the nature of sialic acids present in the cytosolic and membrane fractions 
observed by HPLC, GC-MS analyses were carried out. Figure 3-4 gives an example of the 
total mass profile of sialic acids in the microsomes prepared from the uninvolved colonic 
mucosa.  
    The sialic acids observed using fluorometric HPLC and GC-MS were in good agreement 
(summarized in Table 3-1). Both Neu5,9Ac2 and Neu5,8,9Ac3 were found in the 
glycosidically linked sialic acids present in the cytosolic and membrane fractions, while 
Neu5,9Ac2 was the only free O-acetylated sialic acids observed in the cytosolic fraction. 
However, Neu5,7Ac2 detected by fluorometric HPLC was not observed by GC-MS analysis. 
It is unclear why Neu5,7Ac2 was not detected by GC-MS analysis. One possible explanation 
may be due to the propensity of acetyl groups present at C-7 of sialic acid to migrate to C-9 
[9]. 
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Figure 3-4 Mass Spectrometric Analyses of Microsomal Sialic Acids from Human Colonic Mucosa. 
The purified sialic acids were converted to their pertrimethylsilylated ester/ether derivatives and applied to a GC-
system coupled with EI-MS and analyzed according to a fragmentation scheme by Kamerling et al. (1975) [110]. 
The characteristic fragments of individual sialic acids are indicated by arrows. 
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Table 3-1 Nature of Sialic Acids Present in Human Colonic Mucosa. Purified glycosidically linked or 
free sialic acids in the cytosolic or the microsomal fractions were analyzed by fluorometric HPLC and GC-MS as 
described in section 2.2.4, page 24. 
 
Subcellular fractions Fluorometric HPLC GC-MS 
Cytosol 
 
Neu5Ac 
Neu5,7Ac2 
Neu5,9Ac2 
Oligo-O-acetylated Neu5Ac 
Neu5Ac 
Neu5,9Ac2 
Neu5,8,9Ac3 
Microsomes 
 
Neu5Ac 
Neu5,7Ac2 
Neu5,9Ac2 
Oligo-O-acetylated Neu5Ac 
Neu5Ac 
Neu5,9Ac2 
Neu5,8,9Ac3 
Neu5,7,8,9Ac4 
Free sialic acids in cytosol Neu5Ac 
Neu5,9Ac2 
Neu5Ac 
Neu5,9Ac2 
 
 
3.2 The Sialate-7(9)-O-Acetyltransferase in Human Colonic 
Mucosa 
3.2.1  Substrate Specificity 
The 7(9)-OAT activities in the microsomal and cytosolic fractions were assayed as described 
in sections 2.2.5, page 26, against various exogenous substances including EBNS (96 µg 
sialic acid), de-O-acetylated HCM, CMP-Neu5Ac (600 µM) and Neu5Ac (600 µM), as well 
as endogenous sialic acid-acceptors. In a standard enzyme assay, the microsomal or the 
cytosolic protein was incubated, in the presence and absence of a potential exogenous 
acceptor substrate, with [3H]AcCoA, the donor substrate for 7(9)-OAT [33;34]. In the assay 
procedure reported here, 2 M propionic acid (pH 2.3) was used instead of other frequently 
used acids, such as PCA [37], to stop the enzyme reaction. The benefit of this method was 
that glycosidically linked O-acetylated sialic acids can be directly released following heating 
without the need for a protein precipitation step, which therefore significantly reduces not 
only the loss of O-acetyl groups, but also the time required to perform the assay. Similarly, 
2 M propionic acid was also used to stop incubations performed in the presence of CMP-
Neu5Ac. This resulted in the hydrolysis of CMP-linked sialic acids, thus allowing sialic acids 
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to be easily purified by ion-exchange chromatography on DOWEX 2 X 8. The hydrolysis of 
CMP-Neu5Ac using 0.1 M HCl was not performed, since not only does this result in a 
significant loss of O-acetyl esters [76], but also the Cl- formed cannot be removed by 
lyophilization. The latter is important, if the direct analysis of un-purified sialic acids by TLC 
is required, since the effectiveness of TLC is considerably affected by the presence of salts. 
    Enzyme assay was also carried out using 600 µM of sialyllactose (α2,3- or α2,6-linked) as 
exogenous acceptors. The reaction was stopped by heating at 95 °C for 5 min instead of 
propionic acid, and the enzyme products were analyzed by radio-TLC. Moreover, GD3 
(600 µM) was tested as a potential substrate for the 7(9)-OAT, and the products were assayed 
by either radio-TLC or HPTLC immuno-overlay.  
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Figure 3-5 Sialate-7(9)-OAT Activity Against Different Potential Acceptor Substrates. Fifty µg of 
microsomal membrane protein (black bar), cytosolic protein (white bar) or heating-denatured protein (gray bar), 
prepared from human colonic mucosa, was incubated with [3H]AcCoA under optimal conditions (see Figure 3-
17, page 55) in the presence and absence of a number of possible exogenous acceptor substrates. The products of 
the reaction were purified and the 7(9)-OAT activity was determined using the procedure described in section 
2.2.5, page 26. In the case that sialyllactoses and GD3 were used as exogenous substrates, the endogenous 
glycoconjugates were removed by precipitation after the enzyme incubation, and only the supernatants were 
analyzed. One unit of 7(9)-OAT activity is defined as the amount of enzyme that will transfer 1 pmol acetate 
from AcCoA to sialic acids per minute at 37 °C, pH 7.0. 
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    As can be seen in Figure 3-5, no enzyme activity was observed in the cytosolic fraction, 
neither using exogenous nor endogenous sialic acid-acceptor substrates, while the 
incorporation of [3H]acetyl groups, into endogenous sialic acids and a number of exogenous 
acceptor substrates, was observed when the membrane proteins were used. Furthermore, the 
incubation of heat-denatured membrane fractions with [3H]AcCoA in the presence and 
absence of various acceptor substrates did not result in the incorporation of radiolabeled 
acetate (Figure 3-5). This suggests that the incorporation of radiolabeled acetyl groups onto 
endogenous and exogenous acceptor substrates is occurring enzymatically, probably via the 
action of a sialate-7(9)-OAT present in the microsomal fraction. 
    Of all the exogenous acceptor substrates tested, upon the incubation with [3H]AcCoA and 
the microsomal membrane proteins, the incorporation rate of [3H]acetyl groups into CMP-
Neu5Ac is higher than that observed into other exogenous and endogenous substrates (Figure 
3-5). The 7(9)-OAT activity observed against endogenous substrates is probably due to the 
presence of residual endogenous CMP-Neu5Ac in the isolated microsomal pellet fractions. 
That is, endogenous CMP-Neu5Ac following enzymatic O-acetylation would not only be 
detected following assays using exogenous Neu5Ac and CMP-Neu5Ac as acceptors, but also 
when performing assays using sialoglycoconjugates, such as EBNS and de-O-acetylated 
HCM as substrates. In the latter case, however, Neu5,9Ac2 would be transferred from newly 
formed CMP-Neu5,9Ac2 to endogenous glycoconjugate acceptors via the action of an 
endogenous sialyltransferase, resulting in the formation of acid-insoluble products which 
could be detected using the assay system employed.  
    When GD3 and sialyllactoses were used as the substrate, the enzyme reactions were 
stopped by either organic solvent or heating. Under such conditions, the radioactive 
incorporation into sialic acids linked to endogenous glycoconjugates can not be released. 
Therefore, no 7(9)-OAT activity against endogenous substrate were detected in these cases 
(Figure 3-5). 
    De-O-acetylated HCM was a poor acceptor substrate for the membrane-bound sialate-7(9)-
OAT, even though HCMs secreted by the human colonic mucosa are highly O-acetylated in 
vivo [93;94;103]. Similarly, EBNS and free Neu5Ac were also poor substrates, with the 
incorporation of [3H]acetate being only slightly increased over that observed for endogenous 
substrates. No enzyme activity against sialyllactose and GD3 was observed. Therefore, CMP-
Neu5Ac was used as the exogenous substrate in further characterization studies. 
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3.2.2 Identification of Neo-Synthesized O-Acetylated Sialic Acids by Radio-TLC 
The nature of O-acetylated sialic acids formed was identified, following mild acid hydrolysis 
of the resulting enzyme products and sialic acid purification, using radio-TLC on silica gel 60 
HPTLC plates or cellulose plates.  
    Figure 3-6 provides an example of the confirmation of O-acetylated sialic acids formed by 
radio TLC on silica gel plates. The incubation of membrane proteins in the absence of CMP-
Neu5Ac resulted in a low level of incorporated radioactivity (Figure 3-6C). However, as can 
be seen in Figure 3-6A, two radioactive peaks were observed in the presence of CMP-
Neu5Ac, one of which (peak 1) co-migrated with Fe3+/orcinol/HCl-stained authentic 
Neu5,9Ac2 and the other (peak 2) with oligo-O-acetylated sialic acids. These radioactive 
peaks can be saponified by an overnight incubation in the presence of ammonium vapor 
(Figure 3-6B), suggesting that radioactive ester groups had been formed upon incubation of 
membrane proteins with [3H]AcCoA. 
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Figure 3-6 Radio-TLC Analysis of Purified O-Acetylated Sialic Acids on HPTLC Silica Gel Plate. 
Following the incubation of microsomal membrane protein (50 µg) with [3H]AcCoA and 600 µM CMP-
Neu5Ac, the enzyme products were hydrolyzed, purified and analyzed by radio-TLC on silica gel plates, which 
was developed in methanol:chloroform:20 mM CaCl2 (5:4:1, v/v/v). Radiolabeled sialic acids, before (A) and 
after (B) saponification, were analyzed using an automatic TLC-linear analyzer. Control (C) incubation was 
performed in the absence of CMP-Neu5Ac. The migration distance of Fe3+/orcinol/HCl reagent-stained authentic 
Neu5,9Ac2 is indicated. Peak 1, Neu5,9Ac2; Peak 2, oligo-O-acetylated sialic acids; 3, acetic acid. 
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    The radio-TLC performed on cellulose plates also verifies the formation of O-acetylated 
Neu5Ac following the incubation of microsomal protein with [3H]AcCoA and CMP-Neu5Ac 
(Figure 3-7). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-7 Radio-TLC Analysis of Purified O-Acetylated Sialic Acids on Cellulose Plate. Following 
the incubation of microsomal membrane protein (50 µg) with [3H]AcCoA and 600 µM CMP-Neu5Ac, the 
enzyme products were hydrolyzed, purified and analyzed by TLC on cellulose plates. TLC plates were 
developed in butanol:propanol:0.1 M HCl (1:2:1, v/v/v). Radiolabeled sialic acids were analyzed using an 
automatic TLC-linear analyzer. Control (B) incubation was performed using heating-denatured proteins. The 
migration distance of Fe3+/orcinol/HCl reagent-stained authentic Neu5,9Ac2 is indicated. Peak 1, Neu5,9Ac2; 
Peak 2, oligo-O-acetylated sialic acids; 3, acetic acid. 
 
3.2.3 Identification of Neo-Synthesized O-Acetylated Sialic Acids by Radio-
HPLC 
In order to further confirm the nature of O-acetylated sialic acids being formed, HPLC 
analysis was performed. Fluorometric HPLC affords a better separation of sialic acids, and is 
faster and more specific than radio-TLC. Therefore, its use, in conjunction with the sialate-9-
O-acetyl-specific esterase (sialate-9-O-acetylesterase) of influenza C virus and the sialate-
pyruvate-lyase, as well as alkaline treatment, was adopted in order to confirm the formation of 
O-acetylated sialic acid. 
    Figure 3-8A shows that a number of radioactive peaks (1-3) were observed, however, only 
two of these possessed retention times characteristic for O-acetylated sialic acids. The 
retention time for peak 2 corresponded with that of authentic Neu5,9Ac2, while the retention 
time for peak 3 corresponded to that of authentic oligo-O-acetylated Neu5Ac (Figure 3-8F). 
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The other observed radioactive peak (peak 1), however, seems not to result from the action of 
sialate-7(9)-OAT, since the same peak was also observed by HPLC analysis of a control 
sample, in which [3H]AcCoA was incubated with microsomal proteins in the absence of 
CMP-Neu5Ac (Figure 3-8E). Radioactive peak 1 is probably the result of the degradation of 
[3H]AcCoA to free acetate, with this peak previously been identified in our laboratory, by 
HPLC analyses, as being free acetate (unpublished data).  
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Figure 3-8 Radio-HPLC Analyses of Purified O-Acetylated Sialic Acids. Following the incubation of 
microsomal protein with [3H]AcCoA and CMP-Neu5Ac, the resulting enzyme products were hydrolyzed, 
purified and incubated with: A, PBS (pH 7.0) at 37 °C for 2 h; B, sialate-pyruvate-lyase at 37 °C for 2 h; C, 
0.1 M NaOH at 37 °C for 30 min and D, influenza C virus at 37 °C for 1 h. Purified sialic acids treated in this 
manner, together with authentic BSM sialic acid standards, were analyzed by fluorometric HPLC. Fractions of 
1.0 mL were collected and radioactivity determined via scintillation counting. Control was afforded by the 
incubation of microsomal membrane protein with [3H]AcCoA in the absence of CMP-Neu5Ac (E). The elution 
of BSM sialic acid standards was monitored fluorometrically as described in section 2.2.4.7, page 25. Peak 1, 
acetic acid; Peak 2, Neu5,9Ac2; Peak 3, oligo-O-acetylated Neu5Ac. 
 
 
   As can be further seen in Figure 3-8E (insert), a small amount of radiolabeled product 
corresponding to peaks 2 and 3 was also observed in the control incubation. These products 
are almost certainly due to the presence in the microsomal fraction of a low molecular weight 
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endogenous substrate, probably CMP-Neu5Ac, which was capable of acting as an acceptor 
for the 7(9)-OAT. 
    In further investigations, the incubation of purified sialic acids, prior to HPLC, with sialate-
pyruvate-lyase resulted in over 90 % of the radioactivity associated with peak 2 being lost 
(Figure 3-8B). The complete saponification of peaks 2 and 3 was achieved by pre-incubating 
sialic acid samples in 0.1 M NaOH prior to HPLC analyses (Figure 3-8C), suggesting that the 
incorporated radiolabel was primarily occurring as O-acetyl esters. In a further experiment, 
purified sialic acids were incubated with influenza C virus, prior to radio-HPLC (Figure 3-
8D). This resulted in the loss of 82 % of the radioactivity associated with peak 2, however, no 
other peaks were affected following the treatment with influenza C virus. Taken together, 
these results strongly indicate that the main O-acetylated sialic acids formed following the 
incubation of the membrane fraction prepared from human colonic mucosa with [3H]AcCoA 
and CMP-Neu5Ac was Neu5,9Ac2, with a significant amount of oligo-O-acetylated sialic 
acids also being formed. 
 
3.2.4 Evidences that Free CMP-Neu5Ac Acts as the Acceptor Substrate for 7(9)-
OAT 
The stability of CMP-Neu5Ac under the condition used for enzyme assay was checked by 
TLC analysis on silica gel plates. In comparison with the standard (Figure 3-9, lane 4), CMP-
Neu5Ac was not hydrolyzed after being incubated with PK buffer containing 50 mM KCl, 
pH 7.0 at 37 °C for 15 min (Figure 3-9B, lane 1). However, the majority of CMP-Neu5Ac 
was hydrolyzed to CMP and Neu5Ac following an incubation in the presence of 2 M 
propionic acid at 80 °C for 15 min (Figure 3-9, lane 2) or heating at 95 °C for 5 min (Figure 
3-9, lane 3). 
    The TLC analysis of CMP-Neu5Ac used in 7(9)-OAT activity determinations revealed the 
existence of a contaminant that could be stained with Fe 3+/orcinol/HCl reagent. This 
contaminant was found to co-migrate on silica-TLC with authentic Neu2en5Ac (Figure 3-9, 
Lane 7). Since Neu2en5,9Ac2 has been found to occur in nature [122], the possibility that 
Neu2en5Ac could act as an acceptor substrate was investigated. However, no activity was 
detected when Neu2en5Ac was incubated together with [3H]AcCoA and microsomes (Figure 
3-10). Furthermore, substrate specificity studies also showed that Neu5Ac was not as 
effective an acceptor substrate as CMP-Neu5Ac (Figure 3-5). These results suggest that the 
degradation product of CMP-Neu5Ac, primarily Neu5Ac, as well as Neu2en5Ac, are not 
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acting as the acceptors for 7(9)-OAT when CMP-Neu5Ac is being used to determine enzyme 
activity. 
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Figure 3-9: Stability of CMP-Neu5Ac under the Condition for Enzyme Assay. Analysis of CMP-
Neu5Ac was carried out on a silica gel plate following Lane 1-incubation at 37 °C for 15 min in PK buffer 
containing 50 mM KCl; Lane 2-incubation with 2 M propionic acid at 80 °C for 15 min; Lane 3-incubation at 
95 °C for 5 min in PK buffer containing 50 mM KCl; Lane 4, 5, 6, 7-standard CMP-Neu5Ac, Neu2en5Ac and 
Neu5,9Ac2 standard in PK buffer containing 50 mM KCl, respectively. The silica gel plate was developed in 
methanol:chloroform:20 mM CaCl2 (5:4:1, v/v/v), and the sialic acids were stained with BIAL reagent. 
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Figure 3-10  Utilizing Neu2en5Ac as the Potential Exogenous Substrate for Colonic 7(9)-OAT. 
Following the incubation of microsomal protein (50 µg) with [3H]AcCoA, using either 300 µM Neu2en5Ac (A) 
or 600 µM CMP-Neu5Ac (B) as the exogenous acceptor substrate, the resulting enzyme products were 
hydrolyzed, purified, and analyzed by TLC on silica gel plates (methanol:chloroform:20 mM CaCl2, 5:4:1, 
v/v/v). The migration distance of Fe3+/orcinol/HCl reagent-stained authentic Neu5,9Ac2 is indicated.  
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    In order to further demonstrate that CMP-Neu5Ac can act as the acceptor substrate for the 
sialate-7(9)-OAT, additional investigations were undertaken to isolate the putative product, 
CMP-Neu5,9Ac2, resulting from the incubation of microsomal proteins with [3H]AcCoA and 
CMP-Neu5Ac. For this purpose, enzyme incubations were stopped with ethanol, following 
which the enzyme products were isolated by ion-exchange chromatography on DEAE 
Sepharose FF.  
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Figure 3-11 The Separation and Analysis of CMP-Neu5,9Ac2 by Radio-TLC on Cellulose Plates. 
Microsomal protein was incubated with AcCoA and CMP-Neu5Ac using the standard enzyme assay described in 
section 2.2.5.1, page 26. The standard enzyme reaction used to produce CMP-Neu5,9Ac2 was stopped using 
either ethanol, to avoid product hydrolysis (A1 and A2) or propionic acid, to promote product hydrolysis (A3 
and A4). The enzyme products isolated by ion exchange chromatography were then applied to cellulose plates 
and developed in ethanol:1 M NH4OAc, pH 7.3 (7:3, v/v). Controls were provided by the incubation of 
microsomal protein with AcCoA in the absence of CMP-Neu5Ac (A2 and A4). Peak 1, CMP-Neu5,9Ac2; 
Peak 2, Neu5,9Ac2; Peak 3, oligo-O-acetylated Neu5Ac; 4, free acetate. 
 
 
    As can be seen in Figure 3-11, four radioactive peaks (1-4) were observed on radio-TLC, 
while only radiolabeled peak 4 was observed following the incubation performed in the 
absence of CMP-Neu5Ac (control). Peaks 2 and 3 were identified as Neu5,9Ac2 and oligo-O-
acetylated Neu5Ac, respectively, since they co-migrated with the corresponding authentic 
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standards. Peak 4 is free acetate. The identification of peak 1 as being CMP-Neu5,9Ac2 was 
afforded by radio-TLC analysis of the isolated products after stopping the enzyme reaction 
with propionic acid instead of ethanol. Radio-TLC analysis of enzyme products isolated in 
this manner resulted in the complete disappearance of peak 1 with a corresponding increase in 
the radioactivity associated with peak 2 (Neu5,9Ac2) (Figure 3-11A3), suggesting that CMP-
Neu5,9Ac2 was hydrolyzed by propionic acid to produce Neu5,9Ac2 and CMP. Again, only 
radioactive peak 4 was observed for the corresponding control incubations performed in the 
absence of CMP-Neu5Ac (Figure 3-11A4). 
    Furthermore, all radioactive peaks observed in Figure 3-11 were susceptible to alkaline 
treatment with ammonium vapor (Figure 3-12B1-4). The radioactivity associated with peak 4 
also disappeared since acetic acid, being volatile, is easily removed when TLC plates are 
dried, following ammonium treatment, under a stream of cold air. 
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Figure 3-12 Saponification of O-Acetylated Sialic Acids. Saponification of the radioactive peaks 
observed in Figure 3-11 was fulfilled by incubating the TLC plate in a tightly sealed chamber saturated with NH3 
vapor overnight. After dried with a stream of cold air, the plate was analyzed again by an automatic TLC-linear 
analyzer. 
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3.2.5 Radiolabeled-CMP-Neu5,9Ac2  as Sialic Acid Donor for ST 
To conclusively demonstrate that CMP-Neu5,9Ac2 was formed by the action of a membrane-
bound 7(9)-OAT in the presence of CMP-Neu5Ac and AcCoA, putative radiolabeled CMP-
Neu5,9Ac2 isolated by ion exchange chromatography was used as the donor substrate for ST. 
Two ST activities were utilized, the ST activity associated with the Golgi-enriched fraction 
prepared from human colonic tissues, and the α2,6-ST from rat liver. As shown in Figure 3-
13, the incubation of CMP-[3H]Neu5,9Ac2 with either rat liver α2,6-ST (EC. 2.4.99.1) or 
human colonic Golgi ST resulted in the transfer of [3H]Neu5,9Ac2 onto asialofetuin. No 
incorporation of radioactivity into asialofetuin was observed when heat-denatured Golgi ST 
was used as the enzyme source, while low activity was detected if exogenous substrate was 
absent. 
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Figure 3-13 Utilization of CMP-[3H]Neu5,9Ac2 as Sialic Acid Donor for Rat Liver α2,6-ST and 
Human Colonic Golgi STs. CMP-[3H]Neu5,9Ac2 was used as the sialic acid donor and asialofetuin as the 
acceptor for ST from: 1, rat liver (α2,6-ST) and 2, Golgi-enriched fraction prepared from human colonic 
mucosa. The control (3) was afforded by denaturing Golgi protein prior to the determination of ST activity, 
while control (4) was performed by incubating a Golgi-enriched fraction with CMP-[3H]Neu5,9Ac2 in the 
absence of asialofetuin. The rat liver α2,6-ST activity against CMP-Neu5,9Ac2 was set at 100%. 
 
 
3.2.6  Subcellular Localization of the 7(9)-OAT 
Using a discontinuous sucrose density gradient, subcellular membranes (fractions A-D) were 
isolated from human colonic mucosa. ST activity was used as the specific marker enzyme for 
the Golgi apparatus. In a typical preparation, the highest ST activity was localized in fraction 
A (Figure 3-14). Using CMP-Neu5Ac as the acceptor substrate, the highest sialate-7(9)-OAT 
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activity was, likewise, restricted primarily to fraction A, strongly suggesting that the 7(9)-
OAT is localized in the Golgi-enriched fraction. 
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Figure 3-14 Co-localization of ST and 7(9)-OAT Activity in Golgi-enriched Membrane Fraction. 
Subcellular membrane fractions were isolated from human colonic mucosa using a discontinuous sucrose density 
gradient as described in section 2.2.1.3 (procedure 1), page 21. The activity of the Golgi marker enzyme, ST 
(gray bar), and 7(9)-OAT (black bar) in the crude homogenate, as well as in the different membrane fractions 
(A-D) were determined. One unit of ST activity is defined as the amount of enzyme that will transfer 1 nmol 
Neu5Ac from CMP-Neu5Ac to asialofetuin per hour under the experimental conditions used. 
 
 
3.2.7  Dependence of 7(9)-OAT Activity on the Membrane Integrity 
Saponin is a natural steroid that interacts with cholesterol in membranes. At various 
concentrations, saponin can form 100 nm to 100 µm wide pores in membranes, through which 
not only the ions and other small molecules, but also various macromolecules such as 
colloidal gold-catalase and -albumin can pass [123;124]. Therefore, saponin was used to 
investigate to what extent 7(9)-OAT activity is dependent on membrane integrity.  
    As shown in Figure 3-15, the activity of the microsomal 7(9)-OAT was decreased by 20 % 
and 50 % at a saponin concentration of 0.002  % and 0.01 %, respectively. Total loss of 
enzyme activity was observed at a saponin concentration of 0.05 %. Likewise, the enzyme 
activity was decreased by 50 % at 0.01 % saponin when Golgi vesicles were used as the 7(9)-
OAT source.  
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Figure 3-15 The Effect of Saponin on 7(9)-OAT Activity. Using CMP-Neu5Ac as the exogenous 
substrate, 50 µg of microsomal proteins was incubated with [3H]AcCoA in the presence of saponin at various 
concentrations. The enzyme activity was determined using the procedure described in section 2.2.5.1, page 26. 
The enzyme activity detected in the absence of saponin was set at 100 % (control). 
 
 
    Additionally, the influence of Triton X-100, a non-ionic detergent, on 7(9)-OAT activity 
was investigated. As shown in Figure 3-16, the enzyme activity was significantly decreased in 
the presence of Triton X-100 whose concentration is above its critical micellar concentration 
(about 0.015 %, v/v) [125]. From the results obtained here, it is clear that the activity of 7(9)-
OAT is strictly dependent on membrane integrity. 
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Figure 3-16 The Effect of Triton X-100 on 7(9)-OAT Activity. One hundred µg of microsomal protein 
was incubated with Triton X-100 at the concentrations indicated. Following a 30 min incubation at 4 °C, the 
suspension was immediately used for the determination of 7(9)-OAT activity using CMP-Neu5Ac as acceptor 
substrate. The maximal activity detected in the absence of Triton X-100 was set at 100 % (control). 
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3.2.8  Optimal Conditions for 7(9)-OAT Assay 
Using CMP-Neu5Ac as the exogenous substrate, the influences of temperature, pH, time, 
protein concentration, substrate concentration, and potential inhibitors as well as amino acid-
modifying reagents on the activity of 7(9)-OAT were investigated. Microsomes prepared from 
the same colonic mucosa were used for all investigations. For all parameters investigated, 
only one factor was varied at any given experiment, with all other factors being kept constant 
or near their optimal values.  
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Figure 3-17 Influences of Various Parameters on the Incorporation of [3H]-Acetyl Groups into CMP-
Neu5Ac. The influences of protein concentration (A), time (B), pH (C) and temperature (D) on 7(9)-OAT 
activity were investigated using CMP-Neu5Ac as the acceptor substrate in PK buffer containing 50 mM KCl.  
Enzyme incubations were performed for panel A at 37 °C, pH 7.0; for 15 min; for panel B at 37 °C, pH 7.0 
containing 50 µg protein; for panel C at 37 °C for 15 min containing 50 µg of protein and for panel D at pH 7.0 
for 15 min containing 50 µg of protein. 
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    As shown in Figure 3-17, under the experimental conditions used (outlined in the figure 
legend), the incorporation of [3H]acetyl groups into CMP-Neu5Ac was linear up to a protein 
concentration of 50 µg in a final reaction volume of 30 µL (1.7 mg/mL) (Figure 3-17A) and 
for time points up to 20 min (Fig. 17B). The 7(9)-OAT activity was also found to possess a 
pH optimum of 7.0 (Figure 3-17C) and a temperature optimum of 37 °C (Figure 3- 17D). 
Therefore, all sialate-7(9)-OAT activity determinations were performed at 37 °C in PK buffer 
containing 50 mM KCl for 15 min at a protein concentration of 1.7 mg/mL. 
 
3.2.9  Determination of KM Values for CMP-Neu5Ac and AcCoA 
Under optimal conditions, the effects of both donor and acceptor substrate concentrations 
were studied. The 7(9)-OAT activity was found to be dependent on both the concentrations of 
AcCoA and CMP-Neu5Ac (Figure 3-18). The apparent KM value was determined according 
to the Lineweaver-Burk method. Apparent KM values of 6.1 µM and 59.2 µM were obtained 
for AcCoA (Figure 3-18A) and CMP-Neu5Ac (Figure 3-18B), respectively. 
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Figure 3-18 Dependence of Sialate-7(9)-OAT Activity on Substrate Concentrations. Fifty µg of 
microsomal membrane protein was incubated at varying concentrations of AcCoA (A) and CMP-Neu5Ac (B) 
under optimal conditions (37 °C, 15 min, PK buffer containing 50 mM KCl). The concentration of CMP-
Neu5Ac in panel A was 600 µM and the concentration of AcCoA in panel B was 8.3 µM. KM values were 
determined according to the method of Lineweaver-Burk. 
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3.2.10  Influence of CoA on 7(9)-OAT Activity 
CoA was found to be able to inhibit previously reported OATs [5;6;35;37]. To investigate the 
influence of CoA on the activity of human colonic 7(9)-OAT, the enzyme assay was carried 
out under optimal condition (37 °C, 15 min, PK buffer containing 50 mM KCl) in the 
presence of CoA at different concentrations. Figure 3-19 shows that CoA is a competitive 
inhibitor of the human colonic 7(9)-OAT, with an apparent Ki for CoA of 11.8 ± 4.2 µM 
determined by the method of Dixon et al. (1958) [114]. 
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Figure 3-19 Determination of the Ki Value for CoA. Microsomal membrane protein (50 µg) was 
incubated at concentrations of CoA between 0 and 20 µM together with 8 µM AcCoA (dot) and 16 µM AcCoA 
(square). 7(9)-OAT activity was determined as described in section 2.2.5.1, page 26. The Ki value was 
determined as described by Dixon et al. (1958) [114]. 
 
 
3.2.11  Effects of Amino Acid-Modifying Reagents on 7(9)-OAT Activity 
Previous studies on enzymatic O-acetylation of sialic acids in rat liver [36] and bovine 
submandibular glands showed  [35] that amino acids such as cysteine, lysine and tryptophan 
and histidine were important for full enzyme activity. In order to determine which of those 
residues is involved in the sialate O-acetylation in human colonic Golgi vesicles, the enzyme 
assays were carried out in the presence of different amino acid-modifying reagents.  
    As shown in Table 3-2, the activity of 7(9)-OAT decreased considerably in the presence of 
p-CMB, however, DTT has no influence on the 7(9)-OAT activity. These results suggest that 
at least one free thiol group is essential for the enzymatic O-acetylation of sialic acids in 
human colonic mucosa, while the internal thiol esters and disulfide bridges are not involved in 
this procedure. Furthermore, the inhibitory effect of DEPC on the enzyme activity suggests 
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that histidine, tyrosine or lysine may play important roles. At a concentration of 2 mM, the 
lysine-modifying reagent acid anhydride did not show significant influence on the enzyme 
activity. On the other hand it inhibited the enzyme activity at the concentration of 10 mM. 
This is presumably due to the instability of this inhibitor in aqueous solution, thus, higher 
concentration was required. 
 
Table 3-2 Effects of Various Amino Acid-Modifying Reagents on colonic 7(9)-OAT Activity. Golgi 
vesicles were incubated with CMP-Neu5Ac and [3H]AcCoA in the presence of amino acid-modifiers at the 
concentration indicated. 7(9)-OAT activity was determined using the standard assay procedure described in 
section 2.2.5.1, page 26. 7(9)-OAT activity determined in the absence of amino acid-modifiers was set at 100 % 
(control). The data shown here are expressed as the mean ± SD of two separated experiments. 
 
Reagents Target Amino Acid % of Control (Mean ± SD) 
Control - 100 
2 mM p-CMB Cys (thiols) 32±7 
2 mM acetic acid anhydride Lys 90±5.7 
10 mM acetic acid anhydride Lys 40.7±17 
2 mM DEPC His, Tyr, Lys 47.4±14 
1 mM DDT Cys-Cys (-S-S-) 101.4±11.4 
 
 
 
3.3  The Pathway of Sialate O-Acetylation in Human Colonic 
Mucosa Golgi Vesicles 
3.3.1  Intactness and Topography of Golgi Vesicles 
To be of physiological significance, it is critical that intact and correctly orientated Golgi 
vesicles be used for topological studies of 7(9)-OAT. For this purpose, several methods were 
tried to prepare the high quality Golgi vesicles from human colonic mucosa. The method 
described by Lepers et al. (1979) [21] was adopted but with some modifications so as to 
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increase the recovery of intact Golgi vesicles. The integrity and orientation of Golgi vesicles 
was determined in two ways. 
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Figure 3-20 Topography and Intactness of Golgi Apparatus-Derived Vesicles. A-ST activity in Golgi 
vesicles was assayed as described in Alhadeff and Holzinger (1979) [84] in the presence and absence of either 
Trition X-100 or the exogenous acceptor asialofetuin. B-ST activity of Golgi vesicles prior to and after treatment 
with trypsin. The trypsin treated Golgi vesicles (protein:trypsin=150:1,w/w) were prepared as described in 
section 2.2.8, page 31, and the ST activity against asialofetuin subsequently measured. 
 
 
    A quantitative evaluation of the intactness and orientation level of the isolated Golgi 
vesicles was determined by comparing the ST activity against exogenous substrate in the 
presence and absence of detergent. As shown in Figure 3-20A, the ST activity against the 
endogenous substrates was minimal, either in the presence or absence of Triton X-100. 
However, the ST activity against asialofetuin in the presence of Triton X-100 was 6 times of 
that detected in the absence of Triton X-100, indicating that about 80 % of the Golgi vesicles 
were correctly orientated. 
    Furthermore, Figure 3-20B shows that 25 % of ST activity was lost when Golgi vesicles 
were pre-treated with trypsin, while the treatment of detergent-disrupted Golgi vesicles with 
trypsin resulted in the complete abolishment of ST activity. Taken together, these results 
show that at least 75 % of Golgi vesicles prepared using the procedure described in section 
2.2.1.3, page 21, were intact and correctly orientated. 
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3.3.2  Lumenal Orientation of 7(9)-OAT in the Golgi Vesicles 
A widely used method for studying the topology of a membrane-associated enzyme is to 
determine the sensitivity of the enzyme activity to protease digestion [115]. As shown in 
Figure 3-21, 94 % of the enzyme activity was retained in the Golgi vesicles pre-treated with 
trypsin. Since at least 75 % of the Golgi vesicles used were intact and correctly orientated, 
these results suggest that the 7(9)-OAT, at least its active site, is located on the lumenal side 
of isolated Golgi vesicles.  
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Figure 3-21 Protection of 7(9)-OAT Activity from Trypsin Digestion. Golgi vesicles were treated with 
trypsin (protein:trypsin=150:1, w/w) at 25 °C for 10 min in 20 mM potassium phosphate buffer, pH 7.0, 
containing 50 mM KCl and 0.25 M sucrose. The incubation was stopped by the addition of the same ice-cold 
buffer. After centrifugation at 100 000 x g for 30 min, the Golgi vesicles were surface-washed and used for the 
determination of 7(9)-OAT activity using the procedure described in section 2.2.5.1, page 26. 7(9)-OAT activity 
detected in Golgi vesicles prior to trypsin treatment was set at 100 %. 
 
 
3.3.3 Incorporation of [3H]AcCoA into Lumenal CMP-Neu5Ac in the Golgi 
Vesicles 
As shown in the preceding section, the lumenal localization of 7(9)-OAT indicates that 
enzymatic O-acetylation of CMP-Neu5Ac occurs in the Golgi lumen. To verify this, CMP-
Neu5Ac preloaded Golgi vesicles were incubated with [3H]AcCoA, and the radioactivity 
incorporated into free sialic acid was analyzed by radio-TLC on silica gel plate.  
    As shown in Figure 3-22, in comparison to 7(9)-OAT activity detected in non-CMP-
Neu5Ac-preloaded Golgi vesicles, a significant increase in the enzyme activity was observed 
in the Golgi vesicles preloaded with CMP-Neu5Ac for 5 min (Figure 3-22). This suggests that 
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the enzymatic O-acetylation of CMP-Neu5Ac occurs in the Golgi lumen by the lumenal 
localization of 7(9)-OAT. However, extended preloading time did not further increase 7(9)-
OAT activity, in fact pre-loading vesicles for 30 min actually led to a decrease in the 
incorporation of [3H]acetate into CMP-Neu5Ac. The simplest interpretation of this 
phenomenon is that the activity of 7(9)-OAT is dependent on the concentration of CMP-
Neu5Ac in the Golgi lumen.  
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Figure 3-22 Dependence of 7(9)-OAT Activity on the Concentration of Golgi Lumenal CMP-Neu5Ac. 
Fifty µg of Golgi proteins was preloaded with 500 µM CMP-Neu5Ac in 50 µL of 50 mM Tris-HCl buffer, 
pH 7.45, containing 10 mM MgCl2 and CompleteTM protease inhibitor, at 30 °C for time points up to 30 min. 
After terminating CMP-Neu5Ac transport, Golgi vesicles were pelleted, washed and immediately incubated with 
[3H]AcCoA under the standard reaction condition outlined in section 2.2.10, page 32. The resulting enzyme 
products was analyzed, following mild acid hydrolysis and purification, using radio-TLC on cellulose plates 
(propanol:butanol:0.1M HCl, 2:1:1, v/v/v). 
 
 
    The concentration of CMP-Neu5Ac in the Golgi lumen is regulated by a number of factors. 
First is the transport of CMP-Neu5Ac from cytosol into the Golgi lumen by a specific CMP-
Neu5Ac transporter [23]. It has been reported that the transport of CMP-Neu5Ac occurs 
rapidly with linear time pointing up to few minutes [19]. Once transported into the Golgi 
lumen, CMP-Neu5Ac can act as a substrate for STs which transfer Neu5Ac onto 
glycoconjugates, or alternatively be hydrolyzed [19;22], resulting in the reduction of CMP-
Neu5Ac concentration in the Golgi lumen. Taken together, it is highly probable that Golgi 
vesicles preloaded with CMP-Neu5Ac for 5 min possessed a lumenal concentration of CMP-
Neu5Ac higher than those preloaded for extended times. Extended preloading times, which 
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would not further increase the lumenal concentration of CMP-Neu5Ac but even possible 
decreases it, leads to a plateau and then a decrease in the production of CMP-Neu5,9Ac2.  
 
3.3.4 Involvement of CMP-Neu5Ac Transporter into the Sialate O-Acetylation 
in Human Colonic Mucosa Golgi Vesicles 
It has been shown that human colonic 7(9)-OAT catalyzes the O-acetylation of CMP-Neu5Ac 
in the lumen of Golgi vesicles, using AcCoA as the donor substrate. However, both CMP-
Neu5Ac and AcCoA are not synthesized in the Golgi vesicles [37;126;127], which suggests 
that CMP-Neu5Ac and AcCoA must be transported from the cytosol into the Golgi lumen 
where they can then act as substrates for 7(9)-OAT. Therefore, the influence of various 
inhibitors of the transport of CMP-Neu5Ac and AcCoA on 7(9)-OAT activity was 
investigated. 
    A number of studies show that CMP and CMP-sialic acids derivatives are able to inhibit 
the translocation of CMP-sialic acids by CMP-Neu5Ac transporter [19;26;128]. Utilizing this 
knowledge, a two-step procedure was adopted to selectively inhibit the transport of CMP-
Neu5Ac. First, Golgi vesicles were preloaded with CMP-Neu5Ac in the presence of various 
known CMP-Neu5Ac transport inhibitors. After the removal of the inhibitor and non-
transported CMP-Neu5Ac, the Golgi vesicles were immediately incubated with [3H]AcCoA. 
The 7(9)-OAT activity resulting from these incubations was then determined. The structures 
of inhibitors used are shown in Figure 3-23.  
    The non-penetrating probe, DIDS, is a widely used inhibitor of the anion transport, in 
particular of the sugar-nucleotide transport system in the Golgi apparatus [115;129]. The fact 
that DIDS does not penetrate the membrane, and thus does not affect the anionic-binding 
enzymes facing the Golgi lumen, provides us the ability to study the influence of CMP-
Neu5Ac and AcCoA transport on 7(9)-OAT.  
    Figure 3-24 shows that DIDS can efficiently inhibit the activity of 7(9)-OAT. This was not 
the result of the direct inhibitory effect of DIDS on OAT, which has been shown here to be 
localized in the Golgi lumen. DIDS has been previously reported to be able to inhibit both 
CMP-Neu5Ac transporter and AcCoA transporter by binding to the basic amino acid residues 
facing the cytoplasmic side [37;115]. Thereby, the lack of enzyme substrates in the Golgi 
lumen led to the decrease of 7(9)-OAT activity.  
    To selectively inhibit the CMP-Neu5Ac transporter, two known specific inhibitors (CMP 
and KI-8110) [130;131] were used. As shown in Figure 3-24, 7(9)-OAT activity was reduced 
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in a concentration-dependent manner when Golgi vesicles were preloaded with CMP-Neu5Ac 
in the presence of CMP. However, no such effect was observed when KI-8110 was used to 
inhibit CMP-Neu5Ac transport. In fact, at the concentration of 2 mM, no significant influence 
of KI-8110 on 7(9)-OAT was observed, while 1 mM CMP was capable of reducing the 
enzyme activity by 50 %. It has been previously shown that 1 mM KI-8110 is not an effective 
inhibitor of CMP-Neu5Ac transporter as CMP, while only 50 % inhibition being observed 
even at a concentration of 10 mM [131]. Nevertheless, the observation that KI-8110 could not 
inhibit the preloading of Golgi vesicles with CMP-Neu5Ac is surprising. 
 
RS CH2 CH2CH2 C
O
CH2N
H
N
H
C
O
C C CH2 O P
O
O OP-OCH2
H
H
O
P
O-
O-O
H
OH
H
NC
C N
CH
C
N
HC
N
NH2
O
O-HO
H CH3
CH3 O-
R=H, coenzyme A
R=CH3COO-; Acetyl coenzyme A
 
                                                                   
 
OOCH2
H
H
OH
H
OH
H
C
CH
C
N
C
N
NH2
OO
O-
HO P
CMP
O
COOH
   CH3- C - HN
HO
HO
HO
HO
O
OOCH2
H
H
OH
H
OH
H
C
CH
C
N
C
N
NH2
OO
HO P
O
CMP-Neu5Ac
      
 
KI-8110
O
COOCH3
CH3CH2   HN
AcO
AcO
AcO
AcO
O O
H
H
O
H
O
H
C
C
C
N
C
N
NH2
O
F
SCN
SO3Na SO3Na
CH CH NCS
DIDS   
Figure 3-23 Structures of CMP-Neu5Ac and AcCoA Transporter Inhibitors Used in the Experiments.  
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    CoA was also found to be able to reduce the formation of O-acetylated CMP-Neu5Ac. It 
has been previously observed that CoA could be transported into the Golgi lumen [37], in this 
case a lumenal CoA could inhibit the 7(9)-OAT. It is also possible that CoA could inhibit the 
transport of CMP-Neu5Ac, since a number of other nucleotides, including AMP, are known 
to be able to inhibit this process [19;132]. A combination of the two effects can also not be 
ruled out. 
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Figure 3-24 Involvement of CMP-Neu5Ac Transporter into Sialate O-Acetylation in Human Colonic 
Mucosa Golgi Vesicles. The incubations of Golgi vesicles with CMP-Neu5Ac (500 µM) were performed in the 
absence (control) or presence of CMP, DIDS, CoA, KI-8110 under the conditions described in section 2.2.9, 
page 31. After washing and centrifugation steps, the Golgi vesicles were immediately incubated with 
[3H]AcCoA. The resulting enzyme products were analyzed, following acid hydrolysis, using radio-TLC on silica 
gel plates (methanol:chloroform:20 mM CaCl2, 5:4:1, v/v/v). The radioactive incorporation detected in the 
control was set at 100 %. The bars show the SD values of two experiments. 
 
 
3.3.5 Involvement of AcCoA Transporter in Sialate O-Acetylation in Human 
Colonic Mucosa Golgi Vesicles  
In order to study the importance of the AcCoA transport on sialate O-acetylation in human 
colonic mucosa, CMP-Neu5Ac-preloaded Golgi vesicles were incubated with [3H]AcCoA in 
the presence and absence of CoA, DIDS and CMP, and the activity of 7(9)-OAT was 
determined. The enzyme activity detected in the absence of AcCoA transporter inhibitors was 
set at 100 %. 
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    CoA is a competitive inhibitor of the putative AcCoA transporter [5;35;37], while DIDS 
inhibits AcCoA transport in a similar fashion to how it inhibits other transport processes [37]. 
Because of the procedure used, the transport of CMP-Neu5Ac into the Golgi lumen occurred 
prior to the addition of CoA and DIDS, that is, only the transport of AcCoA can be 
influenced. Therefore, as shown in Figure 3-25, the depletion of the AcCoA pool in the Golgi 
lumen by the addition of AcCoA transporter inhibitors resulted in a decrease in the O-
acetylation of CMP-Neu5Ac. Moreover, the inhibitory effect of CoA was concentration-
dependent, which is in agreement with the fact that CoA is a competitive inhibitor of the 
AcCoA transporter, and strongly suggests that sialate O-acetylation in the colonic Golgi 
vesicles is regulated by the transport of AcCoA. 
    Moreover, as shown in Figure 3-25, CMP was found to decrease the 7(9)-OAT activity in a 
concentration-dependent way. This was not the result of the inhibitory effect of CMP on 
CMP-Neu5Ac transport, since CMP was added after the preloading of Golgi vesicles with 
CMP-Neu5Ac. However, it has been reported that CMP could be transported into Golgi 
lumen [133], and thus could inhibit the 7(9)-OAT. Another possibility is that CMP could 
inhibit the transport of AcCoA, since both CMP and CoA have a nucleoside moiety. It is also 
due to the combination of the two effects.  
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Figure 3-25 Participation of the AcCoA Transporter in the Sialate O-Acetylation in Human Colonic 
Mucosa Golgi Vesicles. CMP-Neu5Ac-preloaded Golgi vesicles were incubated with [3H]AcCoA in the absence 
(control) and presence of the substances indicated above. The resulting enzyme products were hydrolyzed and 
analyzed by radio-TLC on silica gel plates, which were developed in methanol:chloroform:20 mM CaCl2 (5:4:1, 
v/v/v). The radioactive incorporation into sialic acid detected in the control was set at 100 %. The bars show the 
SD values of two experiments. 
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3.3.6 Transferring of Neu5,9Ac2 from CMP-Neu5,9Ac2 to Endogenous 
Glycoconjugates 
It has been shown in the previous sections that in human colonic Golgi vesicles sialate O-
acetylation occurs at the sugar-nucleotide level and is catalyzed by a specific 7(9)-OAT. 
However, in nature, sialic acids are typically found at the terminal position of glycans present 
on glycoproteins and glycolipids [2]. Therefore, investigations were carried out to determine 
if newly synthesized CMP-linked O-acetylated sialic acid could be transferred by endogenous 
STs to glycoprotein and glycolipid acceptors in the same Golgi vesicles. 
    Following the incubation of Golgi vesicles with CMP-Neu5Ac and [3H]AcCoA, DIDS was 
added to terminate transporter activities. The mixtures were then further incubated for the 
times indicated in Figure 3-26. Due to the ability of DIDS to inhibit the transport of CMP-
Neu5Ac and AcCoA, further synthesis of O-acetylated CMP-Neu5Ac could be effectively 
halted without affecting other enzymatic processes, such as the sialyltransferase activity in the 
Golgi lumen. In this way the final destination of O-acetylated sialic acid could be monitored. 
The incorporation of radioactivity associated with free CMP-sialic acid in the acid-soluble 
fraction and glycoconjugate-bound sialic acid in the acid-insoluble fraction was determined 
by radio-TLC on silica gel plates. 
    As shown in Figure 3-26, an increase in the total and acid-soluble radioactivity was 
observed when Golgi vesicles were incubated for a further 1 h after the addition of DIDS. 
This indicates that CMP-Neu5Ac and AcCoA in the Golgi lumen were still being utilized as 
substrates by the 7(9)-OAT for as long as 1 h following the termination of the corresponding 
transport activities. However, following a further 2 h´ incubation post-DIDS addition, no 
further neo-CMP-[3H]Neu5,9Ac2 was synthesized in the Golgi vesicles (Figure 3-26). This 
suggests that DIDS completely blocked the transport of AcCoA and CMP-Neu5Ac. 
    The incorporation of [3H]acetate into the acid-insoluble fraction, on the other hand, 
increased linearly from 1 hour post-DIDS addition to a maximum at 4 h. A corresponding 
decrease in the radioactivity associated with free CMP-sialic acid was also observed at time 
points over 2 h. This indicates that neo-synthesized CMP-Neu5,9Ac2 was transferred to 
endogenous acid-insoluble glycoconjugate-bound sialic acids by a ST associated with human 
colonic Golgi vesicles. It should be noted that ST activities measured against endogenous 
substrate in vitro are generally very low, as was also seen in Figure 3-20A (section 3.3.1, 
page 59). The transfer of approximately 14 % of [3H]Neu5,9Ac2 from newly synthesized 
CMP-[3H]Neu5,9Ac2 into endogenous glycoconjugates is, therefore, significant, and implies 
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that a ST having donor substrate preference for CMP-Neu5,9Ac2 exists in human colonic 
Golgi vesicles. 
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Figure 3-26 The Transfer of Neu5,9Ac2 from Neo-Synthesized CMP-Neu5,9Ac2 to Endogenous 
Glycoconjugates in the Golgi Vesicles. Following the incubation of Golgi vesicles (100 µg) with 200 µM 
CMP-Neu5Ac and [3H]AcCoA (0.25 µCi, 0.3 µM) in 50 mM PK buffer, pH 7.0, at 37 °C for 40 min, DIDS was 
added to a final concentration of 1 mM. The mixtures were then further incubated at 37 °C for 1, 2 and 4 hours, 
following which the reactions were terminated by the addition of propionic acid. The radioactivity associated 
with the acid-soluble and acid-insoluble fractions were analyzed by radio-TLC on silica gel plates 
(methanol:chloroform:20 mM CaCl2, 5:4:1, v/v/v).  
 
 
3.3.7  Incorporation Rate of Neu5Ac to Neu5,9Ac2 onto Various Glycoproteins  
Generally, each sialic acid linkage is generated by a single or more sialyltransferases which 
show the specificity not only for the linkage but also for the acceptor [2;29]. Therefore, the 
direct transfer of Neu5,9Ac2 from CMP-Neu5,9Ac2 to endogenous glycoconjugates should 
depend not only on the synthesis of CMP-Neu5,9Ac2, but also on the acceptor substrate 
specificities of the sialyltransferases involved. To further explore this, the incorporation rate 
of Neu5,9Ac2 into different potential acceptors was compared with that of Neu5Ac by 
employing human colonic Golgi STs and rat liver α2,6-ST (EC.2.4.99.1).  
    As shown in Figure 3-27, using asialofetuin as the acceptor and CMP-Neu5,9Ac2 as the 
donor, a different substrate specificity for the two STs used was observed. Rat liver α2,6-ST 
showed the lower transfer rate of Neu5,9Ac2 compared with that of Neu5Ac, which was 
reduced to 66 %. This is in good agreement with the previous reports [65;67], and indicates 
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that rat liver α2,6-ST is not specific for CMP-Neu5,9Ac2. In contrast, the human colonic 
Golgi STs transferred Neu5,9Ac2 to asialofetuin at a rate 5-fold of that observed for Neu5Ac. 
These results suggest that there might exist one colonic ST preferring to utilize CMP-
Neu5,9Ac2 as the donor substrate. 
    On the other hand, when asialo-BSM was used as the acceptor substrate, the incorporation 
rate of Neu5,9Ac2 to asialo-BSM was decreased when compared with that of Neu5Ac, 
suggesting that asialo-BSM was not the optimal acceptor substrate for Neu5,9Ac2.  
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Figure 3-27 The Incorporation Rate of Neu5,9Ac2 into Asialofeutin or Asialo-BSM by Human Colonic 
Mucosa STs and Rat liver α2,6-ST. Using CMP-[3H]Neu5,9Ac2 (black bar) as the donor substrate, the ST 
activity against asialofetuin (A) and asialo-BSM (B) was determined, respectively. Control was performed using 
CMP-[14C]Neu5Ac (white bar), and the ST activity detected in the control was set at 100 %.  
 
 
3.4 Solubilization of Membrane-Bound Sialate-7(9)-O-
Acetyltransferase 
3.4.1  Pre-Extraction Microsomal Proteins with EDTA, 1 M KCl and Freeze-
Thawing 
The procedure to remove water-soluble and peripheral membrane proteins is called pre-
extraction [134]. Since peripheral proteins are bound to membranes primarily by electrostatic 
and hydrogen-bond interactions, therefore, they usually could be released from the membrane 
by changing the pH or ionic strength, or by using chelating agents [135]. Water-soluble 
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proteins could be removed by disrupting membranes without detergent, following the removal 
of membranes by ultracentrifugation [134]. 
    As shown in Figure 3-28, the treatment of microsomes with EDTA, either at 1 mM or 
100 µM concentration, resulted in a 50 % decrease in enzyme activity of the membrane pellet. 
However, no enzyme activity was observed in the EDTA extraction supernatant. Moreover, 
two cycles of freeze-thawing or 1 M KCl extraction did not release the 7(9)-OAT in the 
supernatant, because 80 % of the enzyme activity remained in the membrane pellet treated in 
such ways (Figure 3-28). These results suggest that 7(9)-OAT cannot be extracted from the 
membrane by pre-extraction. 
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Figure 3-28 Extraction of the 7(9)-OAT Activity Using EDTA, 1 M KCl and Freeze-Thawing. Two 
hundred microgram of microsomal membranes was extracted with EDTA, washed with 1 M KCl, and put 
through 2 freeze-thaw cycles, respectively. After centrifugation at 100 000 x g for 30 min, the resulting 
supernatants (sup) and pellets were used to determine 7(9)-OAT activity. The enzyme activity detected in the 
membrane fractions prior to these treatments was set at 100 % (control). 
 
3.4.2  Solubilization and Stabilization of 7(9)-OAT 
Various detergents including nonionic detergents (Triton X-100, Nonidet P40, LUBROL Px 
and octylglucoside) and zwitterionic detergents (Zwittergent 3-12 and CHAPS) were 
examined for their abilities to solubilize 7(9)-OAT in an active form. The structures of those 
detergents are shown in Appendix II. For each detergent, the solubilization was performed at 
different protein to detergent ratios varying from 10:1 to 1:10. The solubilization efficiency is 
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estimated by quantitative analysis of the 7(9)-OAT activity and protein amount before 
ultracentrifugation and in the supernatant after ultracentrifugation. 
    Of all the detergents tested, CHAPS (0.9 % w/v) was found to be able to solubilize 7(9)-
OAT, however, only a small amount of activity was detected in the soluble form. As shown in 
Figure 3-29A, the incubation of [3H]AcCoA and AcCoA with CHAPS-solubilized 
microsomal membrane proteins resulted in a radioactive peak, co-migrating with authentic 
Neu5,9Ac2 on silica gel plates. However, only about 1 % of the original membrane-bound 
enzyme activity (Figure 3-29B) was recovered in the soluble form.  
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Figure 3-29 Solubilization of 7(9)-OAT from Human Colonic Microsomes with CHAPS. Microsomal 
proteins were solubilized with 0.9 % CHAPS using the procedure described in section 2.2.13.4, page 34. After 
centrifugation at 100 000 x g for 30 min, the supernatant (A) was used for the determination of 7(9)-OAT 
activity against CMP-Neu5Ac. The enzyme activity in the microsomes prior to the addition of CHAPS (B) was 
also determined. The enzyme products were hydrolyzed and analyzed with radio-TLC on silica gel plates 
(methanol:chloroform:20mM CaCl2, 5:4:1, v/v/v). The position of BIAL reagent-stained authentic Neu5,9Ac2 is 
indicated. 
 
 
    To stabilize 7(9)-OAT, DTT and glycerol were added during the solubilization of 
microsomal proteins. The enzyme activity detected in the microsomes prior to the addition of 
CHAPS was set at 100 %. As shown in Figure 3-30, only about 1 % of the membrane 7(9)-
OAT activity was recovered in the soluble form, and the presence of DTT or glycerol did not 
increase this value. 
    Moreover, the binding of enzyme to substrate is thought to be able to increase the protein 
stability. In some cases, this stabilizing effect has been valuable for membrane protein 
isolation [136]. However, the presence of CMP-Neu5Ac during the solubilization of 
microsomal proteins provided no stabilizing effect on the solubilized 7(9)-OAT (Figure 3-30). 
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Figure 3-30 Solubilization of Membrane 7(9)-OAT in the Presence of DTT, Glycerol and CMP-
Neu5Ac. Microsomal proteins were solubilized with 0.9 % (w/v) CHAPS in the presence of 1 mM DTT, 
300 µM CMP-Neu5Ac and 20 % (v/v) glycerol, respectively, as described in section 2.2.13.4, page 34. After 
centrifugation at 100 000 x g for 30 min, the resulting supernatant was used to determine 7(9)-OAT activity 
against CMP-Neu5Ac. The enzyme activity in the microsomes prior to the addition of CHAPS was set at 100 %. 
 
 
    A number of membrane-associated enzymes have been successfully reactivated by the 
addition of lipids following solubilization [137;138]. Hence, lecithin was added to the 
solution of solubilized microsomal proteins, and the activity of 7(9)-OAT was measured. 
Unfortunately, as shown in Figure 3-31, no reactivation of the solubilized 7(9)-OAT was 
achieved in the presence of lecithin. 
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Figure 3-31 Effect of Lecithin on the Activity of Soluble 7(9)-OAT. Microsomal protein was solubilized 
with CHAPS, and used to determine 7(9)-OAT activity against CMP-Neu5Ac, in the absence (A) and presence 
(B) of lecithin-saturated suspension. The resulting enzyme products were hydrolyzed, purified, and analyzed by 
radio-TLC on silica gel plates (methanol:chloroform:20 mM CaCl2, 5:4:1, v/v/v). The migration distance of 
BIAL reagent-stained authentic Neu5,9Ac2 is indicated. 
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3.4.3  Pitfall in the Identification of Radiolabeled Products Resulting from the 
Incubation of Solubilized Microsomal Proteins with [3H]AcCoA 
During the course of trying to solubilize the 7(9)-OAT from microsomes, it was found that 
special attention should be paid when radio-TLC analysis is performed on a cellulose plate, 
which is commonly used for the identification of O-acetylated sialic acids. Following the 
incubation of solubilized microsomal proteins with [3H]AcCoA and CMP-Neu5Ac, the 
resulting enzyme products were hydrolyzed, purified and analyzed with radio-TLC on 
cellulose and silica gel, respectively.  
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Figure 3-32 Radio-TLC Analyses of the Purified Products Resulting from the Incubation of 
Solubilized Microsomal Proteins with [3H]AcCoA and CMP-Neu5Ac. Following the incubation of 
solubilized microsomal proteins with [3H]AcCoA and CMP-Neu5Ac, the products were hydrolyzed, purified as 
described in section 2.2.5.2, page 28, and analyzed with radio-TLC on a silica gel 60 plate (10x10 cm, methanol: 
chloroform: 20 mM CaCl2, 5:4:1, v/v/v) and a cellulose plate (20x20cm, propanol: butanol: 0.1 M HCl, 2:1:1, 
v/v/v), respectively. The migration position of BIAL reagent-stained authentic Neu5,9Ac2 is indicated. 
 
    As shown in Figure 3-32, different chromatographic profiles were obtained, even though 
aliquots from the same sample were analyzed. A radioactive peak co-migrating with authentic 
Neu5,9Ac2 was observed on the cellulose plate (Figure 3-32A), which is sensitive to alkaline 
treatment. However, on the silica gel plate the only radioactive peak observed was at the point 
of origin (Figure 3-32B). These results indicated that the assumed [3H]Neu5,9Ac2 peak on 
cellulose is not O-acetylated sialic acid. This was further confirmed since this product was 
resistant to the action of influenza C virus esterase and sialate-pyruvate-lyase. Therefore, to 
identify O-acetylated sialic acids, it is essential to utilize at least two TLC systems in 
RESULTS 
 72
combination with specific methods, such as the treatment with influenza C virus esterase and 
sialate-pyruvate-lyase. 
    Our findings and the reports of the other groups [4;7;70] showed that the activity of 7(9)-
OAT is extremely sensitive to detergent, and the enzyme activity is strictly dependent on the 
membrane integrity [4;70]. The loss of enzyme activity following solubilizing proteins from 
membranes could be due to a variety of reasons, including the loss of associated cofactors or 
certain subunits. 
 
3.5 Sialate-O-Acetylesterase (OAE): Sialate De-O-Acetylation in 
Human Colonic Mucosa 
3.5.1 Distribution of OAE in Human Colonic Mucosa 
Subcellular fractions (cytosol, lysosomes and microsomes) were simultaneously prepared 
from human colonic homogenates. The ß-galactosidase activity was used as a marker for the 
lysosomal fraction, while sialyltransferase activity was for the microsomal fraction. Table 3-5 
outlines a typical result for the distribution of these marker enzymes in the various fractions 
obtained from the uninvolved colonic mucosa following differential centrifugation. 
 
Table 3-5 The Distribution of  Marker Enzyme Activities in Various Subcellular Fractions Isolated 
by Differential Centrifugation. 1U of galactosidase=1 nmol of MU produced/min.; 1U of ST=1 nmol of 
Neu5Ac transferred /h. 
 
Enzyme Specific 
Activity (U/mg protein) 
Post 3 000 x g 
Pellet 
Lysosome Cytosol Microsome 
ß-galactosidase 3.95 13.4 0 1.2 
Sialyltransfease Not detected Not detected 0 3.6 
 
 
    The expression of O-acetylated sialic acids in human colonic mucosa indicates that the 
OAEs should be present in the same tissue. To verify this, the OAE activity in subcellular 
fractions was assayed by using Neu5,9Ac2, Neu5,7(8),9Ac3 or BSM as the substrate, 
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respectively. Here we refer to the esterase activity against Neu5,9Ac2 as 9-OAE, while that 
against Neu5,7(8),9Ac3 as oligo-OAE.  
    Using BSM as exogenous substrate, quite low esterase activity was observed in the 
cytosolic fraction and the membrane fraction. One explanation for this is that, in vitro, the 
sticky property of BSM hindered the action of esterase. Therefore, we only concentrated on 
the esterase against free O-acetylated sialic acids.  
    As shown in Figure 3-34, the esterase activity against Neu5,9Ac2 or Neu5,7(8),9Ac3 has 
been detected not only in the cytosol but also in the microsomes and lysosomes. However, the 
OAE activity detected in the microsomes was quite low. This is probably the result of residual 
lysosomes being present in the microsomal fraction, as is shown by the presence of ß-
galactosidase activity in the isolated microsomal fraction (Table 3-5). Therefore, these results 
suggest that at least two forms of OAE exist in human colonic mucosa, with one being 
localized in the cytosol, and the other being membrane-associated, most probably in the 
lysosomes.  
    Moreover, the distribution of esterase activity against MU-Ac in different subcellular 
fractions was found to be similar with that of OAE, however, higher enzyme activity was 
detected in the microsomal fraction. 
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Figure 3-34 Subcellular Distribution of OAE Activities in Human Colonic Mucosa. The esterase 
specific activity was measured by incubating subcellular fractions with Neu5,9Ac2 and Neu5,7(8),9Ac3, 
respectively, as described in section 2.2.14, page 35. One unit of OAE activity equals to 1 nmole of acetic acid 
released from O-acetylated sialic acids per min under the experimental condition used. One unit of esterase 
activity against MU-Ac equals to 0.1 mmole of MU released from MU-Ac per min under the condition used. 
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3.5.2  Enzymatic Activity on O-Acetyl Esters from Mono- and Di-O-Acetylated 
Sialic Acids Shows Specificity for the Hydrolysis of 9-O-Acetyl Groups  
To confirm the enzymatic hydrolysis of O-acetyl residues from mono-O-acetylated sialic 
acids, the enzyme products were examined by fluorometric HPLC. As shown in Figure 3-35, 
following the incubation of Neu5,7Ac2 (peak 2) and Neu5,9Ac2 (peak 3) with cytosolic 
proteins, the amount of Neu5,9Ac2 (peak 3) was decreased with a corresponding increase in 
the amount of Neu5Ac (peak 1), while no reduction in the amount of Neu5,7Ac2 was 
observed after short incubation times. However, no degradation of O-acetyl groups from 
Neu5,9Ac2 was observed when denatured proteins were used (Figure 3-35B). Therefore, the 
hydrolysis of mono-O-acetylated sialic acids is catalyzed by an enzyme specific for the 
cleavage of sialate 9-O-acetyl ester. The alkaline treatment of Neu5,9Ac2 resulted in the 
complete de-O-acetylation of Neu5,9Ac2 (Figure 3-35C), identifying peak 4 as being the 
reagent peak. The same results were obtained when membrane proteins were used.  
 
 
D
et
ec
to
r R
es
po
ns
e 
(m
V
)
0
20
40
0 10 20 30 40 0 10 20 30 40 0 10 20 30 40
A B C
Elution Time (min)
1
2
3
1
2
360 1
4
44
 
 
Figure 3-35 Hydrolysis of 9-O-Acetyl Groups from Neu5,9Ac2 by the Cytosolic OAE. Following the 
incubation of cytosolic proteins (A) or heat-denatured proteins (B) with Neu5,9Ac2, the enzyme products were 
examined by fluorometric HPLC. The saponification of Neu5,9Ac2 was fulfilled with 5 % NH3 at 37 °C for 1 h 
(C). Peak 1, Neu5Ac; Peak 2, Neu5,7Ac2; Peak 3, Neu5,9Ac2; Peak 4, reagent peak. 
 
 
    The hydrolysis of Neu5,7(8),9Ac3, a mixture of Neu5,7,9Ac3 and Neu5,8,9Ac3, was also 
studied. Figure 3-36 shows that the non-specific de-O-acetylation of Neu5,7(8),9Ac3 induced 
by alkaline treatment resulted in the formation of Neu5Ac. However, following the incubation 
of this mixture with cytosolic proteins, the reduction in the amount of Neu5,7(8),9Ac3 was 
accompanied with an increase in the level of not only Neu5Ac, but also Neu5,7Ac2 and 
Neu5,9Ac2 (Figure 3-36 and 3-37). This suggests that the enzymatic hydrolysis of 
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Neu5,7,9Ac3 occurred first by cleaving the 9-O-acetyl group, which led to the formation of 
Neu5,7Ac2.  
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Figure 3-36 Hydrolysis of O-Acetyl Groups from Neu5,7(8),9Ac3 by the Cytosolic OAE. Cytosolic 
protein (A) or heat-denatured protein (B) was incubated with 2.5 mM Neu5,7(8),9Ac3, and the enzyme products 
were analyzed by fluorometric HPLC. The saponification of Neu5,7(8),9Ac3 was fulfilled with 5 % NH3 at 
37 °C for 1 h (C). Peak 1, Neu5Ac; Peak 2, Neu5,7Ac2; Peak 3, Neu5,9Ac2; Peak 4, Neu5,7(8),9Ac3/reagent 
peak. 
 
    After 1 h, a drop of Neu5,7Ac2 level and a corresponding increase in Neu5Ac was observed 
(Figure 3-36). Since Neu5,7Ac2 is a poor substrate for the cytosolic OAE as shown in Figure 
3-35, the drop in the level of Neu5,7Ac2 amount observed here was not due to the action of 
cytosolic OAE. On the other hand, it was previously reported that the migration half-life of 
free Neu5,7Ac2 is 4-8 h at physiological conditions (37 °C, pH 7.0) [9]. Therefore, it is likely 
that the spontaneous migration of acetyl group from 7- to 9-position under the condition used 
for esterase assay (37 °C, pH 7.45) resulted in the reduction in the amount of Neu5,7Ac2. The 
resulting Neu5,9Ac2 then can be further hydrolyzed by the cytosolic OAE. 
    Under the condition (37°C, pH 7.45) used for esterase assay, the rate of spontaneous 
migration of the acetyl group from 7- to the 9-position of sialic acid is slow. The possibility of 
the involvement of a migrase, which has been postulated to be able to increase the migration 
rate at least 100-fold, is low because this activity has been found to be localized in 
microsomal fraction [35]. Therefore, the continuously rising in the amount of Neu5,9Ac2 
(Figure 3-37) was not likely to be the result of the isomerization of Neu5,7Ac2, which was 
produced by the enzymatic hydrolysis of Neu5,7,9Ac3.  
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    In contrast, it was reported that the migration of O-acetyl groups from 8- to 9-position may 
occur so fast that Neu5,8Ac2 cannot be isolated in a stable state [9]. Thus, it is proposed that 
the enzymatic de-O-acetylation of Neu5,8,9Ac3 occurs first at the position of 9-O-acetyl 
group, and the acetyl group of the resulting Neu5,8Ac2 undergoes a very rapid migration to 
the 9-position, which leads to an increase in the amount of Neu5,9Ac2. The resulting 
Neu5,9Ac2 could then be hydrolyzed by the cytosolic OAE with a correspondingly increase in 
the amount of Neu5Ac (Figure 3-37). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-37 Positional Specificity of the Cytosolic OAE on O-Acetyl Esters from Neu5,7(8),9Ac3. 
Following the incubation of Neu5,7(8),9Ac3 with cytosolic proteins, the enzyme products were analyzed by 
fluorometric HPLC at various times. Control was performed using heat-denatured proteins. The quantity of sialic 
acid was determined from the area under the individual sialic acid peak obtained following HPLC. 
 
 
3.6 Comparison of the Level of O-Acetylated Sialic Acids and the 
Activities of 7(9)-OAT and OAE in the Uninvolved and 
Cancerous Colonic Mucosa  
3.6.1 A Decrease in the Expression Level of O-Acetylated Sialic Acids in the 
Cancerous Mucosa 
The nature of sialic acids present in the cytosolic and membrane fractions prepared from 
cancerous mucosa was also analyzed by fluorometric HPLC and GC-MS (Table 3-7). The 
presence of  glycoconjugate-bound Neu5Ac and Neu5,9Ac2 in the cytosolic and membrane 
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fractions was confirmed. However, no oligo-O-acetylated sialic acids and Neu5Gc as well as 
free O-acetylated sialic acids were detected by GC-MS analysis. 
 
Table 3-7 The Nature of Sialic Acids Present in the Subcellular Fractions from Cancerous Mucosa.  
Sialic acids were purified from the cytosolic fraction or microsomal fraction, and were analyzed by fluorometric 
HPLC and GC-MS as described in section 2.2.4, page 24. 
 
Subcellular fractions Fluorometric HPLC GC-MS 
Cytosol 
 
Neu5Ac 
Neu5,9Ac2 
Oligo-O-acetylated Neu5Ac (?) 
Neu5Ac 
Neu5,9Ac2 
 
Microsomes 
 
Neu5Ac 
Neu5,9Ac2 
Oligo-O-acetylated Neu5Ac (?) 
Neu5Ac 
Neu5,9Ac2 
 
Free sialic acids in cytosol Neu5Ac 
Neu5,9Ac2 
Oligo-O-acetylated Neu5Ac (?) 
Neu5Ac 
 
 
 
    Using fluorometric HPLC analysis, the relative expression level of O-acetylated sialic acids 
in the uninvolved and cancerous mucosa from the same patient was determined (Table 3-6). 
The level of mono- and oligo-O-acetylated sialic acids in the uninvolved mucosa was 22.4 ± 
10.8 % (n=13) and 5.0 ± 4.6 % (n=13), respectively. These results are compatible with the 
previous reports [94;95]. When compared with the uninvolved mucosa, the cancerous mucosa 
expressed very significantly lower levels of the mono- (t-paired test, p<0.005) and oligo-O-
acetylated sialic acids (t-paired test, p<0.005), however, the higher level of Neu5Ac (t-paired 
test, p<0.0001). This is supposed to be a result of a decrease in the amount of O-acetylated 
sialic acids.  
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Table 3-6 Sialic Acids from the Uninvolved and Cancerous Colonic Mucosa.  
 
    Species of Sialic Acids
  (% of Total Sialic Acids)
Tissue Nr. Neu5Ac Mono-O-Ac-Neu5Ac
Oligo-O-Ac
-Neu5Ac
uninvolved colonic mucosa
13045 82.6 17.4 0
12599 57.7 37.9 4.4
11430 70.8 24.7 4.5
17672 83.3 16.7 0
14730 55.3 43.2 1.5
17421 82.6 8.9 8.5
16413 89.1 9.7 1.2
14445 66.3 20.7 13
25308 81.9 15.1 3.0
26570 57.6 27.8 14.6
25096 70.1 26.5 3.4
17960 84.7 10.9 4.4
26547 62.9 31.8 6.2
72.6±
11.9
22.4±
10.8
5.0±
4.6
cancerous colonic mucosa
13045 92.6 7.4 0
12599 90.4 9.6 0
11430 76.7 21.9 1.8
17672 95.9 4.1 0
14730 88.1 11.9 0
17421 97.4 2.6 0
16413 - - -
14445 89.6 10.4 0
25308 97.4 2.6 0
26570 60.7 39.3 0
25096 92.2 7.8 0
17960 95.9 4.1 0
26547 86.0 14 0
88.6±
10.5
11.3±
10.4
-
 
 
    Moreover, as shown in Figure 3-38, the reduction in the level of O-acetylated sialic acids 
occurs not only in the cytosolic fraction (t-paired test, p<0.005) but also in the membrane 
fraction (t-paired test, p<0.005) from cancerous colonic mucosa. This is different from the 
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previous report that the cancerous colonic mucosa expressed a constant level of mono-O-
acetylated sialic acids, which showed no significant difference from that observed in 
normalcolonic mucosa [95]. The difference between these two investigations is supposed to 
be due to the cancerous tissue samples used representing different cancer stages. 
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Figure 3-38 Relative Amount of O-Acetylated Sialic Acids in Subcellular Fractions from the 
Uninvolved and Cancerous Colonic Mucosa. Sialic acids in the cytosolic and microsomal fractions from 
uninvolved (A) and cancerous mucosa (B) were prepared, purified and analyzed using the procedure described in 
section 2.2.4, page 24. The results shown here were obtained from 12 matched tissue samples. 
 
 
    To perceive the relationship between the reduction extent of mono- and oligo-O-acetylated 
sialic acids in cancerous colonic mucosa and cancer stage, the ratio of the relative level of O-
acetylated sialic acids in the cancerous mucosa to that in the uninvolved mucosa was plotted 
as a function of cancer stage. The cancer stage was judged by TNM classification system 
(appendix III) [104]: stage I to IV.  
    As shown in Figure 3-39, no apparent correlation was found between the cancer stage and 
the decreasing extent of mono- and oligo-O-acetylated sialic acids. Of 12 cancerous samples 
at stages II-IV, the significant reduction or complete loss of oligo-O-acetylated sialic acid was 
observed.  
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Figure 3-39 Relationship between the Decrease Extent of O-Acetylated Sialic Acids and Cancer Stage. 
The cancer malignancy was assessed by the TNM classification system. Of 12 samples investigated, 5 were in 
stage 2, 5 were in stage 3, and 2 were in stage 4. 
 
 
3.6.2 The Reduction of OAT Activity in Cancerous Colonic Mucosa  
To explore the underlying mechanism for the alteration of O-acetylated sialic acid level in 
cancerous mucosa, the activities of OAE and OAT in the uninvolved and cancerous mucosa 
from the same patient were determined and compared.  
    As shown in Figure 3-40, the activities of 9-OAE and oligo-OAE were observed in both the 
uninvolved mucosa and cancerous mucosa. Comparison of the activities of 9-OAE and oligo-
OAE between cancerous and uninvolved colonic mucosa from the same patient shows no 
significant difference in enzyme activities in the cytosolic, microsomal and lysosomal 
fractions (t-paired test, p>0.05).  
    In contrast to OAE, the activity of 7(9)-OAT against CMP-Neu5Ac in cancerous mucosa 
was significantly decreased (t-paired test, p<0.05), when compared with that detected in the 
uninvolved mucosa from the same patient (Figure 3-41). Taken together, the results obtained 
here suggest that the decrease in the activity of 7(9)-OAT in cancerous colonic mucosa results 
in the reduction of O-acetylated sialic acid amount in cancerous tissues. 
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Figure 3-40 Comparison of the OAE Activities in Various Subcellular Fractions from the Uninvolved 
and Cancerous Colonic Mucosa. The activities of 9-OAE and oligo-OAE in the cytosol (n=12), microsomes 
(n=12) and lysosomes (n=5) were determined as described in section 2.2.14, page 35. The bars show the mean ± 
SD. 
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Figure 3-41 A Decrease in the Activity of 7(9)-OAT in Cancerous Colonic Mucosa. Using CMP-
Neu5Ac as acceptor substrate, the activity of 7(9)-OAT in the uninvolved colonic mucosa (n=12) and cancerous 
mucosa (n=6) were measured as described in section 2.2.5, page 26. 
 
3.6.3 Regulation of the Amount of Glycoconjugate-bound O-Acetylated Sialic 
Acids by OAT and Lse 
Lse is proposed to participate in the degradation of O-acetyl groups present on 
sialoglycoconjugates in the lysosomal compartment [63], while OAT is responsible for the 
biosynthesis of O-acetylated sialic acids. Therefore, the relative activity of OAT to lysosomal 
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OAE might be responsible for the amount of total O-acetylated sialic acids associated with 
glycoconjugates.  
    Figure 3-42 shows that, in both the uninvolved and cancerous tissues, the higher ratio of the 
OAT/Lse activity corresponds to the higher level of glycoconjugate-bound O-acetylated sialic 
acids. A correlation coefficient of 0.8 (Spearman´s rank correlation, appendix IV), for 
uninvolved or cancerous colonic mucosa, indicates a very good relationship between the two 
variables investigated. It thus suggests that the balance of OAT and Lse plays an important 
role in keeping the constant amount of glycoconjugate-bound O-acetylated acetylated sialic 
acids in human colonic mucosa. 
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Figure 3-42 Correlation between the Amount of Glycoconjugate-bound O-Acetylated Sialic Acids and 
the Relative Activity of OAT to Lysosomal OAE. The amount of total glycoconjugate-bound O-acetylated 
sialic acids was plotted against the relative activity of OAT to lysosomal OAE. The line was fitted by regression 
analysis and the coefficient of correlation (rs) for the two variables were determined by Spearman´s rank 
correlation.  
 
 
3.6.4 Regulation of the Free Cytosolic O-Acetylated Sialic Acid Amount by 
Cytosolic OAE 
It has previously been proposed that cytosolic OAE is involved in the degradation of free O-
acetylated sialic acids in the cytosol [63]. Therefore, the relationship between the amount of 
free O-acetylated sialic acids in the cytosol and the activity of cytosolic OAE was 
investigated. In the cytosolic fraction prepared from colonic mucosa, the level of oligo-O-
acetylated sialic acids was quite low, therefore, only the amount of free mono-O-acetylated 
sialic acids in the cytosol was plotted against the activity of cytosolic 9-OAE. 
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    As shown in Figure 3-43, the higher level of cytosolic 9-OAE activity was accompanied 
with the lower level of cytosolic free mono-O-acetylated sialic acids. For uninvolved colonic 
mucosa, the correlation coefficient was -0.35 (Spearman´s rank correlation), suggesting that 
the function of cytosolic 9-OAE is to remove O-acetyl groups from free O-acetylated sialic 
acids. With regard to cancerous mucosa, the existence of free Neu5,9Ac2 was not confirmed 
by GC-MS analyses, therefore, the relationship of the amount of cytosolic free mono-O-
acetylated sialic acids and the level of cytosolic 9-OAE activity was not analyzed.  
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Figure 3-43 Relationship between Cytosolic 9-OAE Activity and the Amount of Cytosolic Free Mono-
O-Acetylated Sialic Acids. The amount of cytosolic free mono-O-acetylated sialic acids was plotted against 
cytosolic 9-OAE activity. The line was fitted by regression analysis and the coefficient of correlation (rs) for the 
two variables wasdetermined by Spearman correlation rank.  
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4  Discussion 
4.1  O-Acetylated Sialic Acids Level and Human Colorectal Cancer 
4.1.1  The Nature of Sialic Acids in Human Colonic Mucosa 
To estimate the patterns and relative amounts of O-acetylated sialic acids in human colonic 
mucosa, most analyses were limited to the periodate oxidation and colorimetric estimations of 
sialic acid concentration [121;139-142], paper chromatography [93;94], TLC [142] and HPLC 
[69;95]. Hutchins et al. (1988, 1988a) [93;94], however, confirmed the existence of mono-, 
di- and tri-O-acetylated sialic acids in normal human colonic mucosa and carcinoma cells by 
FAB-MS (fast atom bombardment-mass spectrometry) analysis. Those studies show that the 
level of O-acetylated sialic acids is up to 50 %, with above 30 % being oligo-O-acetylated 
sialic acids. 
    In the investigations reported here, the nature of sialic acids in the microsomal membrane 
and cytosolic fractions prepared from uninvolved human colonic mucosa (the excised end of 
colon tissue resected for carcinoma) was confirmed for the first time by GC-MS. N-
Acetylneuraminic acid (Neu5Ac) and its O-acetylated derivatives were the only sialic acids 
observed. The presence of glycoconjugate-bound Neu5,9Ac2 and Neu5,8,9Ac3 in the 
cytosolic and membrane fractions, and of free Neu5,9Ac2 in the cytosolic fraction were 
confirmed. The presence of Neu5,7,8,9Ac4 in the membrane fraction was also confirmed. The 
similarity of the results obtained from fluorometric HPLC analysis and GC-MS shows the 
reliability of fluorometric HPLC analysis. 
 
4.1.2  Reduction of Oligo-O-Acetylated Sialic Acids is an Early Event of 
Malignant Transformation in Human Colorectal Cancer 
The expression of O-acetylated sialic acids in human colonic tissues shows racial 
variability [69], which is assumed to be the distribution of a single dominant gene regulating 
sialate O-acetylation (oat). About 9 % of the Caucasian population is homozygous (oat-oat-) 
for sialate O-acetylation, and this ratio is increased in Asians. In this case, the loss of O-
acetylated sialic acids seems not to be related to any disease but is probably due to gene 
mutation resulting from the selection pressure [69]. With this exception, the reduction of O-
acetylated sialic acids is believed to be a phenomenon occurring in the development of 
neoplasma [69;143].  
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    It has been reported that the oligo-O-acetylated sialic acids in normal human colonic tissues 
is above 30 %, while the mono-O-acetylated sialic acids level ranges between 10-15 % 
[94;144]. When compared with these literature values, the uninvolved colonic mucosa 
investigated here expressed a relatively high proportion of mono-O-acetylated sialic acids 
(22.4 ± 10.8 %) but the lower level of oligo-O-acetylated sialic acids (5.0 ± 4.6 %). This 
phenomenon has been observed by other groups [94;95]. The abnormal pattern of O-
acetylated sialic acids expressed in the uninvolved colonic mucosa, which are histologically 
normal, is supposed to be the result of a premalignant field defect, rather than a local 
secondary effect of tumor growth [145;146]. The reduced level of O-acetylation in the case of 
ulcerative colitis [147], a potentially premalignant state, supports this suggestion. Moreover, 
the significant reduction or loss of the oligo-O-acetylated sialic acids was observed in the 12 
cancerous samples investigated, which represent stage II to IV. Taken together, our findings 
show that the reduction of oligo-O-acetylated sialic acids in human colonic mucosa is an early 
event during the malignant transformation in human colorectal cancer. The same phenomenon 
was previously observed in the cultured human colorectal cell lines at different stages of the 
adenoma-carcinoma sequence [95].  
    It was also found that cancerous mucosa expresses a significantly lower level of mono-O-
acetylated sialic acids when compared with the uninvolved mucosa from the same patient 
(n=12). However, no apparent correlation was found between the cancer stage and the 
decreasing extent of mono-O-acetylated sialic acid. 
 
4.2  Sialate O-Acetylation in Human Colonic Mucosa 
4.2.1  Characterization of Membrane Sialate-7(9)-O-Acetyltransferase from 
Human Colonic Mucosa 
Since the first discovery of the OAT in bovine submandibular glands more than 30 years 
ago [33;34], the OAT has been extensively investigated in rat liver [36;37;71;148], equine 
submandibular glands [6], guinea pig liver [5], and in K1-positive Escherichia coli [136] as 
well as Chinese Hamster Ovary cells [41]. However, little is known about the underlying 
enzymatic reaction which governs sialate O-acetylation in human colonic tissue, in spite of 
the fact that sialic acids in human colonic mucins are highly O-acetylated, and that a 
relationship between the loss of O-acetylation, as well as 7(9)-OAT activity, and colorectal 
cancer has been reported [95]. 
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    Utilizing microsomal membrane fractions isolated from human colonic mucosa, the 7(9)-
OAT activity against a number of possible exogenous acceptor substrates and endogenous 
substrate was determined. Of all the substrates tested, CMP-Neu5Ac was found to be the best 
acceptor of acetyl groups transferred from AcCoA by OAT. Till now, CMP-Neu5Ac acting as 
an acceptor substrate for the OATs has never been reported. However, not only has 9-O-
acetylated CMP-Neu5Ac previously been isolated from bovine submandibular glands [39], 
but a small, reproducible activity using CMP-Neu5Ac as the acceptor substrate has been 
observed in our laboratory against a soluble 7(9)-OAT activity from bovine submandibular 
glands (unpublished data). 
    The following observations provide evidence that CMP-Neu5Ac is acting as an acceptor 
substrate for a membrane-bound 7(9)-OAT from human colonic tissue. First, the incubation of 
microsomal protein with CMP-Neu5Ac and [3H]AcCoA resulted in the formation of 
Neu5,9Ac2 and oligo-O-acetylated sialic acid. Both products can be saponified by alkaline 
treatment, with that corresponding to Neu5,9Ac2 being susceptible to both the action of the 9-
O-acetyl-specific esterase (sialate-9-O-acetylesterase) from the influenza C virus, as well as 
sialate-pyruvate-lyase. 
    The formation of oligo-O-acetylated sialic acids is not an entirely unexpected observation, 
since this sialic acid was detected by fluorometric HPLC analyses of the microsomal 
membrane fraction isolated from human colonic tissue. It is not clear whether the formation 
of oligo-O-acetylated sialic acids and Neu5,9Ac2 is due to the action of two separate enzyme 
activities catalyzing the O-acetylation at C-7 and C-9 independently, or is due to the action of 
one OAT and a migrase that catalyzes the migration of acetyl groups from C-7 to C-8 or C-9, 
as was postulated to occur in bovine submandibular glands by Vandamme-Feldhaus and 
Schauer (1998) [35]. It must be noted that no Neu5,7Ac2 was observed in this study following 
the incubation of microsomal protein with CMP-Neu5Ac and [3H]AcCoA, neither by radio-
TLC nor radio-HPLC, and only a small amount of Neu5,7Ac2 was detected by fluorometric 
HPLC analyses of various fractions isolated from human colonic mucosa (Table 3-1, page 
45). This suggests that rapid migration of O-acetyl groups, followed by further O-acetylation, 
along the side chain (from C-7 to C-9) might result in the observation, using the techniques 
currently available, of only oligo-O-acetylated sialic acids and Neu5,9Ac2. Only experiments 
utilizing a purified sialate-7(9)-OAT can further shed light on the complex enzymatic reaction 
that governs side chain sialate O-acetylation. 
    Further evidence for the enzymatic O-acetylation of CMP-Neu5Ac by human colonic 7(9)-
OAT was afforded by the isolation of CMP-Neu5,9Ac2, the putative product. This product, as 
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analyzed by radio-TLC on cellulose, was susceptible to alkaline treatment, as well as to mild 
acid hydrolysis, resulting in an increase in the peak intensity associated with Neu5,9Ac2. The 
isolated putative CMP-Neu5,9Ac2 was also capable of being utilized by the purified α2,6-ST 
from rat liver, as well as by Golgi ST from human colonic mucosa. STs can only transfer 
sialic acid to an appropriate glycoconjugate acceptor from CMP-activated sialic acid [149]. 
However, modifications to the sialic acid moiety are tolerated, with a number of C-9-
substituted CMP-Neu5Ac derivatives being found to act as suitable ST donor 
substrates [65;67;150]. Therefore, the finding that [3H]Neu5,9Ac2 can be transferred from 
isolated CMP-[3H]Neu5,9Ac2 to asialofetuin by rat liver and human colonic ST conclusively 
confirms that the product of the incubation of human colonic microsomes with CMP-Neu5Ac 
and [3H]AcCoA is CMP-Neu5,9Ac2. 
    The characterization of the membrane-bound 7(9)-OAT from human colonic mucosa, using 
CMP-Neu5Ac as the exogenous acceptor, was investigated. Table 4-1 summarizes the 
properties of the OATs from human colonic tissues, rat liver [36], guinea pig liver [5], as well 
as bovine and equine submandibular glands [6;35;39]. It can be seen that with regard to 
temperature, temperature, pH, AcCoA affinity, as well as the subcellular localization, the 
colonic 7(9)-OAT shows similar properties to those described in other tissues. The activity of 
membrane OAT, including human colonic 7(9)-OAT is dependent on the membrane integrity, 
and can be competitively inhibited by CoA. Furthermore, the sialate O-acetylation in human 
colonic mucosa requires the involvement of histidine, lysine and free thiol residues. These 
residues have been also found to be essential for enzymatic sialate O-acetylation in rat 
liver [36] and bovine submandibular glands [35]. 
    However, the 7(9)-OAT from human colonic tissue has one property that sets it apart, the 
ability to utilize, with a high affinity, CMP-Neu5Ac as an exogenous acceptor substrate. This 
finding, therefore, raises the question, what is the pathway by which sialate O-acetylation 
takes place in human colonic mucosa? 
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Table 4-1 Properties of the Sialate-O-Acetyltransferases from Various Sources 
 
 Human 
Colonic 
Mucosa 
Rat Liver  
[36] 
Bovine 
Submandibular 
Gland [35] 
Guinea Pig  
Liver [5] 
Equine 
Submandibular 
Gland [6]  
Attachment 
sites of O-
acetyl groups 
Side chain 
(C-7 or C-9) 
Side chain 
(C-7 or C-9) 
Side chain  
(C-7 or C-9) 
Pyranose ring 
(C-4) 
Pyranose ring 
(C-4) 
Subcellular 
location 
Golgi Golgi Golgi and 
cytosol a 
Golgi Fine-membrane 
fraction 
Optimal pH 7 7 7 6.7 6.6 
Optimal 
temp. (°C) 
37 22 37 30 37 
Acceptor 
substrate 
CMP-
Neu5Ac 
endogenous endogenous endogenous endogenous 
KM for 
AcCoA (µM) 
6.1  2.9  1.6 0.6  32.1  
Inhibition by 
CoA 
+ (Ki, 11.8 ± 
4.2 µM) 
+ + + (Ki 4.2 µM) + 
Inhibition by 
p-CMB 
+ + + Not detected Not detected 
Dependency 
on membrane 
integrity 
+ + + + + 
a7(9)-OAT activity in the cytosol was determined using free Neu5Ac as substrate [39] 
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4.2.2 Pathway of Sialate O-Acetylation in Human Colonic Mucosa Golgi 
Vesicles 
Early studies using bovine and equine submandibular glands identified a cytosolic 7(9)-OAT 
activity that could transfer acetyl groups from AcCoA to either exogenous or endogenous free 
sialic acid [39;40]. In these studies it was proposed that the O-acetylation of sialic acids could 
occur at the level of free sialic acids, and that the enzyme product 9-O-acetylated Neu5Ac 
could be then activated to CMP-Neu5,9Ac2, which can be ultilized by STs in the microsomes 
from the same tissues [40;151]. The existence of a real cytosolic OAT is still an open 
question, however, these observations suggest that the sialate O-acetylation might also occur 
prior to its transfer to glycoconjugates. 
    On the contrary, more recent investigations on sialate O-acetylation in rat liver [36;37;152] 
suggest that, with the involvement of a trans-membrane transfer of acetate groups, the O-
acetylation of sialic acids may take place within the lumen of the Golgi apparatus, after the 
transfer of sialic acids to glycoconjugates. Similar results were also obtained for the O-
acetylation of gangliosides in the Golgi-enriched vesicles from human malanoma cells 
[38;72]. Even in bovine submandibular glands, the sialate O-acetylation occurring in the 
membrane fractions appears to take place after the transfer of sialic aicds onto glycoproteins 
and glycolipids [35]. 
    However, in human colonic mucosa, the pathway of sialate O-acetylation is different from 
those previously reported in several aspects [35-37;39;72]. First, the sialate O-acetylation 
occurs prior to the transfer of sialic acids onto glycoconjugates, however, the acetyl group is 
incorporated into CMP-Neu5Ac instead of free or glycosidically linked sialic acids. Second, 
human colonic 7(9)-OAT catalyzes the O-acetylation of CMP-Neu5Ac in the Golgi lumen, 
which requires the lumenal pool of CMP-Neu5Ac and AcCoA.  
    CMP-Neu5Ac can be transported from the cytosol into the Golgi lumen by a CMP-Neu5Ac 
transporter, which can be inhibited by CMP and CMP-sialic acid derivatives [19;24;153]. It 
was found that preloading of Golgi vesicles with CMP-Neu5Ac for short times can result in 
an increase in the activity of colonic OAT, while selective inhibition of CMP-Neu5Ac 
translocation by CMP can lead to the redution of enzyme activity. These observations indicate 
the dependency of enzyme activity on the Golgi lumenal CMP-Neu5Ac concentration, which 
can be regulated by CMP-Neu5Ac transporter activity. 
    A putative transporter specific for AcCoA has been supposed to be essential for the O-
acetylation of sialic acids present on glycoconjugates in rat liver [36] and bovine 
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submandibular glands [35]. In human colonic mucosa, the inhibition of AcCoA transport with 
CoA and DIDS, the two known inhibitors for AcCoA transporter [5;35;37], was found to be 
able to decrease 7(9)-OAT activity. This suggests that a similar AcCoA transporter is also 
required for sialate O-acetylation. 
    In nature, sialic acids are typically found at the terminal position of glycans on the 
glycoconjugates but not in free form. In vivo, the transfer of sialic acids to glycoproteins and 
glycolipids occurs in the Golgi compartment by sialyltransferases. In a functional Golgi 
compartment exist all the elements for sialylation, including sialyltransferases, the suitable 
glycoconjugate acceptors, as well as the specific transporter for the uptake and concentration 
of activated sialic acids [128;153;154]. In vitro, intact and right-orientated Golgi vesicles 
prepared from fresh chilled tissues are believed to contain all these elements, and thus can be 
used for mimicking in vivo sialylation by labeling the endogenous glycoprotein acceptors in 
the Golgi vesicles with radiolabeled CMP-linked sialic acids [152;155]. It was observed that, 
upon the incubation of Golgi vesicles with [3H]AcCoA and CMP-Neu5Ac, [3H]Neu5,9Ac2 
can be directly transferred from the neo-synthesized CMP-[3H]Neu5,9Ac2 to endogenous 
glycoconjugates in human colonic mucosa Golgi vesicles This suggests that 
sialyltransferase(s) is involved into the expression of O-acetylated sialic acids on 
glycoconjugates in colonic mucosa. 
    The formation of CMP-linked oligo-O-acetylated sialic acids, though not confirmed, is 
most likely since a certain amount of oligo-O-acetylated sialic acids is formed following the 
incubation of membrane proteins with AcCoA and CMP-Neu5Ac. It is also observed that the 
incubation of AcCoA with microsomal proteins resulted in the incorporation of acetyl group 
into the glycoconjugates. However, it is difficult to distinguish whether the acetyl group is 
directly incorporated into glycoconjugate-bound sialic acids by another OAT in the human 
colonic Golgi vesicles, or the acetyl groups is first incorporated into endogenous CMP-
Neu5Ac, and the newly produced CMP-Neu5,9Ac2 is utilized by the STs in the same tissue to 
sialylate to the endogenous glycoconjugates. These questions can only be clarified when the 
purification of the enzyme is achieved. 
    As summarized in Figure 4-1, in colonic mucosa, the expression of O-acetylated sialic 
acids present on glycoconjugates involves multiple-step reactions. First, the cytosolic CMP-
Neu5Ac and AcCoA are transported into the Golgi lumen by CMP-Neu5Ac and putative 
AcCoA transporters, respectively. In the Golgi lumen, sialate-7(9)-OAT catalyzes the 
incorporation of the acetyl group from AcCoA into CMP-Neu5Ac, resulting CMP-
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Neu5,9Ac2. Finally, at the action of human colonic STs, Neu5,9Ac2 can be transferred from 
the neo-synthesized CMP-Neu5,9Ac2 to certain glycoconjugate acceptors.  
 
 
Cytosol
1
AcCoA
2
OAT
CMP-
Neu5Ac
Ac
CMP-
Neu5,9Ac2
ST
Neu5,9Ac2CMP
CMP-
Neu5,7(8),9Ac3
?
CMP-
Neu5Ac
3
Neu5,7(8),9Ac3
?
Golgi
 
 
Figure 4-1 Scheme of the Pathway for Sialate O-Acetylation in Human Colonic Mucosa. 1-CMP-
Neu5Ac transporter; 2-AcCoA transporter; 3-glycoprotein. 
 
 
4.2.3  A Sialyltransferase Preferring to Utilize CMP-Neu5,9Ac2 as the Donor 
Substrate to Sialylate Certain Acceptors ? 
Previous investigations on purified STs showed that these enzymes can utilize a number of 
CMP-Neu5Ac substitutes as donor substrate, however, with low efficiency [65;67;150]. The 
transfer of 9-O-acetylated Neu5Ac relative to Neu5Ac has been shown to range from 75 % for 
the bovine Galß1,4GlcNAc-α2,6-sialyltransferase to only 10 % for the bovine GalNAc-α2,6-
sialyltransferase, even though the acceptor substrate used are corresponding to the specificity 
of the ST  investigated [72;150]. These observations suggest that those STs have donor 
substrate specificity for CMP-Neu5Ac. 
    In this investigation, it is found that human colonic STs can not only directly transfer 
Neu5,9Ac2 from neo-synthesized CMP-[3H]Neu5,9Ac2 to endogenous glycoconjugates in the 
same Golgi vesicles, but also showed a preference for utilizing CMP-Neu5,9Ac2 over CMP-
Neu5Ac to sialylate asialofetuin. These results suggest that there exists at least one ST having 
the donor substrate preference for CMP-Neu5,9Ac2 in human colonic mucosa.  
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    However, the incorporation rate of Neu5Ac into asialo-BSM by human colonic STs was 
much faster than that observed for Neu5,9Ac2. The difference between asialofetuin and 
asialo-BSM as the acceptor for Neu5,9Ac2 indicates that the incorporation of Neu5,9Ac2 into 
glycoconjugates is dependent on not only the synthesis of CMP-Neu5,9Ac2 but also the 
existence of a suitable acceptor. A comparison of the oligosaccaharide structures present on 
fetuin and BSM (Table 4-2) suggests that GalNAcα- is not the optimal acceptor for 
Neu5,9Ac2, while Galß1,4GlcNAcß- or/and Galß1,3GalNAcα- appear to be the better 
acceptors.  
 
Table 4-2 Main Neutral Oligosaccharide Structures in Human Colonic Mucin, Bovine 
Submandibular Gland Mucin and Fetuin. 
 
Protein Oligosaccharide Structure  
HCM [82;83]. GalNAcα-Ser/Thr 
 GlcNAcß1,3GalNAcα-Ser/Thr 
 Galß1,4GlcNAcß1,3GalNAcα-Ser/Thr 
 GlcNAcß1,3Galß1,4 GlcNAcß1,3GalNAcα-Ser/Thr 
 Galß1,4GlcNAcß1,3Galß1,4GlcNAcß1,3GalNAcα-Ser/Thr 
BSM [119;156;157] GalNAcα-Ser/Thr (53.3 %) 
 GlcNAcß1,3GalNAcα-Ser/Thr (22.3 %) 
Fetuin [67] Galß1,4GlcNAcß- 
 Galß1,3GalNAcα-Ser/Thr 
 
 
    In human colonic mucosa, the location of O-acetylated sialic acid in glycoconjugates has 
not been established. However, it has been demonstrated that HCMs possess high levels of O-
acetylated sialic acids, and the terminal sequence Galß1,4GlcNAcß-. Therefore, it seems that 
HCMs are the specific acceptor for the human colonic ST specific for CMP-Neu5,9Ac2. 
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Nevertheless, the final conclusion can only be made when the assumed ST(s) is purified, and 
the location of O-acetylated sialic acid in the glycoconjugates synthesized in human colonic 
tissue is established. 
    Previous investigations on OATs suggest that there seems to be more than one distinct 
sialate-O-acetyltranferases in mammals, with one O-acetylating α2,6-linked sialic acids of N-
linked sialoglycoproteins [41;71], and another O-acetylating α2,8-linked sialic acids of 
gangliosides [41]. Our findings suggest that there might exist a third enzyme for the O-
acetylation of sialic acids on oligosaccharides of mucin-type proteins through the formation of 
a CMP-Neu5,9Ac2 intermediate, which can be further transferred to a certain glycoconjugate, 
presumably human colonic mucins, by a ST preferring to use CMP-Neu5,9Ac2 as the donor 
substrate. 
 
4.3 Sialate De-O-Acetylation in Human Colonic Mucosa 
Human colonic tissue is characterized by its high level of O-acetylated sialic acids [82;83;92-
96]. Since O-acetyl esters can hinder or abolish the action of sialidase and sialate-pyruvate-
lyase [55;66;75], it is reasonable to predict the existence of OAE in human colonic tissue. 
Actually, OAE activity has been detected in human faecal extracts [52] and in many 
individual human enteric bacterial strains [158], however, very little is known about the turn-
over and catabolism of the O-acetyl groups in human colonic mucosa.  
    Using free O-acetylated sialic acids as substrates, we have demonstrated the activity of 
OAE in colonic mucosa. The OAE activities are found to be localized either in the cytosolic 
fraction or the membrane fraction, probably, the lysosomal compartment. These results do not 
confirm, but imply that two forms of OAEs with distinct structural properties are present in 
human colonic mucosa, similar to that observed in rat liver and rat colonic mucosa [53;56]. 
One is a cytosolic non-glycosylated OAE (Cse), and the other is a membrane-associated 
glycosylated OAE (Lse) [53;56]. 
    In mammals, most OAEs appear to be highly specifc for the cleavage of 9-O-acetyl groups 
from sialic acids [53;55]. With the aid of fluorometric HPLC analysis, human colonic OAEs 
are found to be specific for the hydrolysis of 9-O-acetyl groups from sialic acids, and the 
complete de-O-acetylation of sialic acids can be achieved in a sequential manner. As shown in 
Figure 4-2, the hydrolysis of di-O-acetylated sialic acids first occurs at the 9-position of sialic 
acids, which results in the formation of Neu5,7Ac2 and Neu5,8Ac2. The migration of O-acetyl 
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group from 7- or 8- to 9-position allows the further degradation of these acetyl groups. This 
observation is agreement with the previous investigation on rat liver [53].  
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Figure 4-2 Proposed Scheme for Sequential Hydrolysis of Di-O-Acetylated Sialic Acids by Human 
Colonic OAE. 
 
4.4 Regulation of the Expression Level of O-Acetylated Sialic Acids 
in Human Colonic Mucosa 
The findings in this study suggest that different factors are involved in the regulation of the 
expression level of O-acetylated sialic acids on glycoconjugates in human colonic mucosa. 
These factors might include the regulation of OATs expression, the control of CMP-Neu5Ac 
and AcCoA transport, the regulation of a CMP-Neu5,9Ac2-specific ST expression, the 
regulation of HCMs synthesis, and the control of O-acetylated sialic acids degradation. 
Among those factors, the balance between OAE and OAT is supposed to be the first potential 
regulation point of the expression of O-acetylated sialic acids.  
    The investigation of the relationship between the level of O-acetylated sialic acids and the 
activities of 7(9)-OAT and OAE in colonic mucosa (12 individual tissue samples) shed light 
on the roles of these enzymes in the regulation of O-acetylation. In human colonic mucosa, 
the higher observed Cse activity is associated with the lower amount of cytosolic free O-
acetylated sialic acids. This observation indicates that Cse is involved in the hydrolysis of O-
acetyl groups from cytosolic free O-acetylated sialic acids. These molecules are poor 
substrates for the CMP sialic acid synthase [150] and the existence of O-acetyl esters hinders 
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the action of sialate-pyruvate-lyase [66;75]. Therefore, it is proposed that the physiological 
function of cytosolic OAE is to facilitate further metabolism of free O-acetylated sialic acid in 
the cytosol.  
    In contrast to Cse, the Lse is believed to act on O-acetyl groups of sialoglycoconjugates to 
facilitate the action of sialidases, which is localized in the lysosomal compartment [2;8]. We 
found that the amount of glycosidically linked O-acetylated sialic acids in human colonic 
mucosa is coordinated well with the relative activity of OAT to lysosomal OAE. This 
indicates that the balance of these two enzymes plays a key role in keeping the normal level 
of glycosidically linked sialic acids in human colonic mucosa. 
    Moreover, the comparison of the activities of OAT and OAE in the uninvolved and 
cancerous mucosa from the same patient showed that a significant reduction in 7(9)-OAT 
activity occurs in the cancerous tissues. On the contrary, no significant difference was 
detected between the OAE activities, neither cytosolic OAE nor membrane OAE, in the 
uninvolved and cancerous mucosa. Therefore, it is proposed that a reduction in 7(9)-OAT 
activity, or more exactly, a changing in the balance of OAT and OAE, is one of the main 
reasons for the decrease in the level of sialate O-acetylation in cancer tissues. 
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5  Summary 
The two main enzymes involved in the metabolism and catabolism of O-acetylated sialic 
acids are acetyl-coenzyme A:sialate-O-acetyltransferase (OAT) for the O-acetylation of sialic 
acids, and sialate-O-acetylesterase (OAE) for the de-O-acetylation of O-acetylated sialic 
acids. The sialic acids present in human colonic mucosa are highly O-acetylated, and the 
decreasing expression level of O-acetylation has been demonstrated to be the result of 
malignant transformation in human colorectal cancer. However, little is known about the 
enzymatic processes for sialate O-acetylation and de-O-acetylation in this tissue, and the 
underlying mechanism for the alteration of O-acetylated sialic acid level in cancerous colonic 
mucosa is not yet clarified.  
    A membrane-bound sialate-7(9)-O-acetyltransferase (7(9)-OAT) has been found in human 
colonic mucosa. This enzyme is different from other reported OATs [5;6;35;37;136], for it 
utilizes CMP-Neu5Ac instead of glycoconjugate-bound sialic acid as the acceptor substrate. 
With the aid of chromatographic and enzymatic techniques, the main O-acetylated sialic acid 
formed is verified to be 9-O-acetylated Neu5Ac, and a significant amount of oligo-O-
acetylated Neu5Ac is also synthesized. Moreover, the utilization of CMP-Neu5Ac as the 
acceptor substrate was confirmed by the isolation and characterization of the putative product, 
CMP-Neu5,9Ac2, using ion-exchange chromatography. The ability of CMP-Neu5,9Ac2 to act 
as a sialic acid donor for sialyltransferases affords the conclusive demonstration for the 
formation of CMP-Neu5,9Ac2. Using CMP-Neu5Ac, the most efficient acceptor substrate of 
all those tested, the 7(9)-OAT activity was found to be optimal at 37 °C, with a pH optimum 
of 7.0. The activity of 7(9)-OAT shows the dependence on protein, CMP-Neu5Ac (KM: 
59.2 µM) and AcCoA (KM: 6.1 µM) concentrations, as well as membrane integrity. The 
enzyme activity could be inhibited by CoA with a Ki of 11.9 µM. Subcellular fractionation 
and protease digestion shows that 7(9)-OAT is localized in the Golgi lumen.  
    In human colonic mucosa, the biosynthesis of CMP-Neu5,9Ac2 appears to occur in the 
Golgi lumen. CMP-Neu5Ac and AcCoA are required to be transported from cytosol into the 
Golgi lumen to act as substrates for 7(9)-OAT. The Neu5,9Ac2 can be directly transferred 
from the neo-synthesized CMP-Neu5,9Ac2 to the endogenous glycoconjugates in the same 
Golgi vesicles. This suggests the existence of a ST preferring to utilize CMP-Neu5,9Ac2 as 
the donor substrate.  
    Moreover, asialofetuin is found to be a much more efficient acceptor for Neu5,9Ac2 than 
asialo-BSM, which shows that Neu5,9Ac2 can be only transferred to certain glycoconjugates. 
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The comparison of the oligosaccharide sequences on fetuin and human colonic mucins shows 
that both contain the terminal sequence of Galß1,4GlcNAcß-. This suggests that human 
colonic mucins seem to be the appropriate acceptor substrate for the ST having donor 
substrate preference of CMP-Neu5,9Ac2  
    The expression of O-acetylated sialic acids is remarkably tissue- and molecule-specific, and 
is developmentally regulated in various systems [4;7;8]. Investigations on OATs, together 
with the analyses of naturally occurring sialic acids, suggest that there must be more than one 
distinct sialate-O-acetyltransferase in mammals, with one O-acetylating α2,6-linked sialic 
acids of N-linked sialoglycoproteins [41;71], and another O-acetylating α2,8-linked sialic 
acids of gangliosides [41]. The data shown here suggest that there might exist a third enzyme 
for the O-acetylation of sialic acids on oligosaccharides of mucin-type proteins through the 
formation of a CMP-Neu5,9Ac2 intermediate, which can be further transferred to certain 
glycoconjugates, presumably mucin-type proteins, by a ST preferring to use CMP-Neu5,9Ac2 
as the donor substrate. It is a pathway different from that observed in rat liver and human 
melanoma cells, which takes place after the transfer of sialic acids onto glycoconjugates in the 
Golgi lumen [37;38]. 
    In this study, the activity of sialate-O-acetylesterase (OAE) has been demonstrated in the 
cytosolic and lysosomal fractions prepared from human colonic mucosa. The OAEs are 
specific for the cleavage of the 9-O-acetyl groups from Neu5,9Ac2 or Neu5,7(8),9Ac3. In the 
latter case, complete de-O-acetylation takes place by sequential enzyme cleavage and 
intermediate migration of ester groups from 7- or 8- to 9-position. Moreover, the data 
presented here suggest that cytosolic OAE seems to be involved in the de-O-acetylation of 
free O-acetylated sialic acids in the cytosol, while lysosomal OAE might play an important 
role in the metabolism of O-acetyl groups on glycosidically bound sialic acids. 
    A comparison of the expression level of O-acetylated sialic acids and the activities of OAT 
and OAE in the uninvolved and cancerous mucosa from the same patient (n=12) shows a 
decrease in the level of O-acetylated sialic acid (both mono-O-acetylated and oligo-O-
acetylated) and in the activity of OAE. However, no difference was observed between the 
activities of cytosolic and lysosomal OAE in the uninvolved and cancerous mucosa (p>0.05). 
These results suggest that the change of OAT activity but not the OAE activity results in the 
decrease in the expression level of O-acetylated sialic acids in cancerous colonic mucosa.  
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6  Zusammenfassung 
Die in den Metabolismus und Katabolismus O-acetylierter Sialinsäuren involvierten beiden 
Hauptenzyme sind die Acetyl-Coenzym A:Sialat-O-acetyltransferase (OAT) für die 
O-Acetylierung von Sialinsäuren und die Sialat-O-acetylesterase (OAE) für die De-O-acety-
lierung von O-acetylierten Sialinsäuren. Die in der humanen Darmmucosa vorkommenden 
Sialinsäuren sind stark O-acetyliert, und ein verringertes Niveau der O-Acetylierung wurde 
als Ergebnis einer malignen Transformation bei der Entstehung von colorectalen Tumoren 
beim Menschen beschrieben. Es ist jedoch sehr wenig über die enzymatischen Prozesse der 
Sialinsäure O-Acetylierung und De-O-acetylierung in diesem Gewebe bekannt und der 
zugrunde liegende Mechanismus der Veränderung des Niveaus der O-Acetylierung in entar-
teter humaner Darmmucosa ist bislang nicht aufgeklärt. 
    Eine membran-gebundene Sialat-7(9)-O-acetyltransferase (7(9)-OAT) wurde in humaner 
Darmmucosa gefunden. Dieses Enzym ist insofern von den bisher beschriebenen OATs 
[5;6;35;37;136] verschieden, als es CMP-Neu5Ac anstelle von glycoconjugate-gebundener 
Sialinsäure als Substrat benutzt. Die Eigenschaften der gebildeten O-acetylierten Sialinsäure 
wurde mit Hilfe von chromatographischen und enzymatischen Techniken bestätigt. So ist 
Neu5,9Ac2 die häufigste O-acetylierte Sialinsäure, aber auch oligo-O-acetylierte Sialinsäuren 
wurden in signifikanten Mengen gefunden. Darüber hinaus wurde CMP-Neu5Ac als Ac-
ceptorsubstrat durch die Isolierung und Charakterisierung des vermutlichen Produktes, von 
CMP-Neu5,9Ac2, durch Ionen-Austausch-Chromatographie bestätigt. Die Möglichkeit, das 
Sialyltransferasen CMP-Neu5,9Ac2 als Sialinsäure-Donor nutzen können, erfordert den ein-
deutigen Nachweis der Bildung dieses Substrates. Mit CMP-Neu5Ac, dem von allen geteste-
ten effizientesten Acceptorsubstrat, war die Aktivität der 7(9)-OAT optimal bei 37 °C und 
hatte ein pH-Optimum von 7,0. Die Aktivität der 7(9)-OAT war sowohl abhängig von der 
Proteinmenge, der CMP-Neu5Ac- (KM: 59,2 µM) und der AcCoA-Konzentration (KM: 
6,1 µM) als auch von der Integrität der Membranen. Die Enzymaktivität konnte durch CoA 
mit einem Ki von 11,9 µM inhibiert werden. Subzelluläre Fraktionierungen und 
Proteaseverdaue zeigten die Lokalisierung der 7(9)-OAT im Golgi-Lumen. 
    In humaner Darmmucosa scheint die Biosynthese von CMP-Neu5,9Ac2 im Golgi-Lumen 
abzulaufen. CMP-Neu5Ac und AcCoA müssen daher aus dem Cytosol in das Golgi-Lumen 
transportiert werden, um dort als Substrate der 7(9)-OAT zur Verfügung zu stehen. 
Neu5,9Ac2 kann dort von dem neu synthetisierten CMP-Neu5,9Ac2 durch Sialyltransferasen 
auf endogene Glycoconjugate übertragen werden. Asialofetuin ist das deutlich effizientere 
Acceptorsubstrat für Neu5,9Ac2 im Vergleich zu asialo-BSM, was darauf hindeutet, dass 
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Neu5,9Ac2 nur auf bestimmte Glycoconjugate übertragen werden kann. Ein Vergleich der 
Oligosaccharid-Sequenzen von Fetuin und humanem Darmmuzin zeigt, dass in beiden die 
terminale Sequenz Galβ(1,4)GlcNAcβ- vorliegt. Dies lässt vermuten, dass humanes Darm-
muzin das entsprechende natürliche Acceptorsubstrat der Sialyltransferasen ist, deren Sialin-
säure-Donor CMP-Neu5Ac in diesem Gewebe ist. 
    Die Expression O-acetylierter Sialinsäuren ist bemerkenswert Gewebe- und Molekül-
spezifisch und ist in verschiedenen Systemen entwicklungs-abhängig reguliert [4;7;8]. Zu-
sammen mit den Analysen natürlich vorkommender Sialinsäuren zeigen Untersuchungen von 
OATs, dass es verschiedene Sialat-O-acetyltransferasen in Säugetieren geben muss, eine für 
O-acetylierte Sialinsäuren in α(2,6)-Verknüpfung auf N-glycosylierten Sialoglycoproteinen 
[41;71] und eine andere für O-acetylierte Sialinsäuren in α(2,8)-Verknüpfung auf Gangliosi-
den [41]. Die hier gezeigten Daten deuten darauf hin, dass möglicherweise ein drittes Enzym 
für die O-Acetylierung von Sialinsäuren auf Oligosacchariden von Proteinen des Muzintyps 
existiert, mit einer zwischenzeitlichen Bildung von CMP-Neu5,9Ac2, welches dann auf die 
Glycoconjugate des Muzintyps durch Sialyltransferasen, die dieses Donorsubstrat bevorzu-
gen, übertragen wird. Dies ist ein anderer Weg als der in Rattenleber und humanen Melanom-
Zellen beobachtete, wo die O-Acetylierung erst nach einer Übertragung der Sialinsäuren auf 
die Glycoconjugate im Golgi-Lumen stattfindet [37;38]. 
    In dieser Untersuchung konnte die Aktivität einer Sialat-O-acetylesterase (OAE) in den 
cytosolischen und lysosomalen Fraktionen von humaner Darmmucosa nachgewiesen werden. 
Die OAEs spalten spezifisch die 9-O-Acetyl-Reste von Neu5,9Ac2 oder Neu5,7(8),9Ac3 ab. 
Im letzteren Fall kommt es durch einen sequentiellen enzymatischen Abbau der O-Acetyl-
Reste von Position 9 mit anschließender Migration der verbleibenden Reste von den 
Positionen 7 bzw. 8 nach Position 9 zu einer vollständigen De-O-acetylierung. Darüber hinaus 
deuten die Daten darauf hin, dass cytosolische OAE für die De-O-acetylierung von freien 
Sialinsäuren im Cytosol verantwortlich sind, während die lysosomalen OAE eine wichtige 
Rolle im Metabolismus der O-Acetyl-Reste von glycosidisch gebundenen Sialinsäuren 
spielen. 
    Ein Vergleich der Expression von O-acetylierten Sialinsäuren und der Aktivitäten von 
OAT und OAE in nicht-kanzerösem und kanzerösem Darmgewebe derselben Patienten 
(n=12) zeigt einen Rückgang der O-acetylierten Sialinsäuren (sowohl mono- als auch oligo-
O-acetyliert) und auch der Enzymaktivität der OAE. Es konnte jedoch kein Unterschied zwi-
schen den Enzymaktivitäten der cytosolischen und der lysosomalen OAE in nicht-kanzerösem 
und kanzerösem Darmgewebe nachgewiesen werden (p>0,05). Diese Ergebnisse zeigen, dass 
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eine Veränderung der OAT-Aktivität, aber nicht der OAE-Aktivitäten, für den Rückgang der 
Expression von O-acetylierten Sialinsäuren in kanzeröser Darmmucosa verantwortlich ist. 
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Appendixes  
 
Appendix I Structures of Amino Acid-Modifying Reagents Used in the 
Inhibition Experiments 
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Appendix II  Structures of Detergents Used in Solubilization 
 
 
 
 
CH3(CH2)10CH2 N
+ (CH2)3 S O
-
O
OCH3
CH3
HO
CH3
3HC
N
N+
SO3
-
H
CH3
OH
OH H
CHAPS
O
C8H17 (OCH2CH2)nOH Triton X-100
O
HO
HOCH2
HO OH
OCH2(CH2)6CH3 Octylglucoside
LUBROL Px
Zwittergent 3-12
CH3(CH2)10(OCH2CH2)9OH
C9H19 OCH2CH2(OCH2CH2)8OH Nonidet P40
APPENDIXES 
 103
Appendix III  TNM Classification of Colorectal Cancer Stage 
The American Joint Committee on Cancer (AJCC) has designated staging by TNM 
classification. TNM definitions: 
 
• Primary tumor (T) 
TX: Primary tumor cannot be assessed. 
T0: No evidence of primary tumor. 
Tis: Carcinoma in situ: intraepithelial or invasion of the lamina propria. 
T1: Tumor invades submucosa. 
T2: Tumor invades muscularis propria. 
T3: Tumor invades through the muscularis propria into the subserosa, or into non-
peritonealized pericolic or perirectal tissues. 
T4: Tumor directly invades other organs or structures, and/or perforates visceral peritoneum. 
• Regional lymph nodes (N) 
NX: Regional nodes cannot be assessed. 
N0: No regional lymph node metastasis. 
N1: Metastasis in 1 to 3 regional lymph nodes. 
N2: Metastasis in 4 or regional lymph nodes.  
• Distant metastasis (M) 
MX: Distant metastasis cannot be assessed. 
M0: No distant metastasis. 
M1: Distant metastasis. 
 
Stage TNM 
0 
I 
II 
III 
IV 
Tis, N0, M0 
T1, N0, M0 /T2, N0, M0 
T3, N0, M0/ T4, N0, M0 
Any T, N1, M0/ Any T, N2, M0 
Any T, Any N, M1 
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Appendix IV  Spearman´s Rank Correlation[a,b] 
Spearman´s rank correlation is a correlation analysis suitable for non-Gaussian population. It 
works by assigning a rank to each observation in each group separately. Then calculate the 
sums of the squares of the differences in paired ranks(di2) according to the formula:  
Rs=1-6*(d12+d22+……+dn2)/[n(n2-1)]  
in which n is the number of observations. 
    Rs is the correlation coefficient, which ranges from –1 to 1 and shows the correlation of the 
variables. 
 
Rs Interpretation  
Rs=0  The two variables do not vary together at all. 
0<Rs<1 The two variables tend to increase or decrease together. 
Rs=1 Perfect positive correlation. 
-1<Rs<0 One variable increases as the other decreases. 
Rs=-1 Perfect negative or inverse correlation. 
 
 
a- http://www.graphpad.com; b-http:// nimitz.mcs.kent.edu 
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